Filename,Document Name,Parties,Agreement Date,Effective Date,Renewal Term,Governing Law,Exclusivity,Post-Termination Services
EuromediaHoldingsCorp_20070215_10SB12G_EX-10.B(01)_525118_EX-10.B(01)_Content License Agreement.pdf,VIDEO-ON-DEMAND CONTENT LICENSE AGREEMENT,"['EuroMedia Holdings Corp.', 'Rogers', 'Rogers Cable Communications Inc.', 'Licensor']","['July 11 , 2006']",07-11-2006,"['At Rogers\' option, this Agreement shall renew for a subsequent term of two (2) years on the terms and conditions herein (the ""Renewal Term"").']","Ontario, Canada",[],[]
FulucaiProductionsLtd_20131223_10-Q_EX-10.9_8368347_EX-10.9_Content License Agreement.pdf,CONTENT DISTRIBUTION AND LICENSE AGREEMENT,"['Producer', 'Fulucai Productions Ltd.', 'ConvergTV', 'CONVERGTV, INC.']","['November 15, 2012']",11/15/12,"['License Term Perpetual, unlimited runs x Other: 2 years Commencing: November 15, 2012']",Florida,"['During the License Term (which is identified in the Deal Terms), Producer agrees that ConvergTV has the exclusive right to exercise the rights granted to it under this Agreement with respect to the Program, including those in Section 1, within the Licensed Territory.']",[]
GopageCorp_20140221_10-K_EX-10.1_8432966_EX-10.1_Content License Agreement.pdf,WEBSITE CONTENT LICENSE AGREEMENT,"['PSiTech Corporation', 'Licensor', 'Licensee', 'Empirical Ventures, Inc.']","['Feb 10, 2014']",02-10-2014,"['Thereafter, this Agreement shall renew automatically for one (1) additional three (3) year period (the ""Renewal Term"" and collectively, together with the Initial Term, the ""Term"") unless either party provides the other with written notice of non-renewal at least ninety (90) days before the expiration of the Initial Term].']",Nevada,"[""Subject to Licensee's on\xadgoing compliance with Section 3.2 and all other terms and conditions of this Agreement, Licensor grants to Licensee an exclusive (save for rights reserved to Licensor hereunder), non-transferable (except as provided in Section 11.7) and non- sublicensable license, during the License Term, to reproduce, perform, display, transmit and distribute the Licensed Content on the Licensee Siteand Related Media intended solely for use by End Usersin the Territory within the scope set forth in Schedule 1 (License Scope), which is attached hereto and incorporated herein by this reference.""]",[]
IdeanomicsInc_20160330_10-K_EX-10.26_9512211_EX-10.26_Content License Agreement.pdf,CONTENT LICENSE AGREEMENT,"['YOU ON DEMAND HOLDINGS, INC.', 'Licensor', 'Licensee', 'Beijing Sun Seven Stars Culture Development Limited']","['December 21, 2015']",12/21/15,[],New York,[],[]
DeltathreeInc_19991102_S-1A_EX-10.19_6227850_EX-10.19_Co-Branding Agreement_ Service Agreement.pdf,CO-BRANDING AND SERVICES AGREEMENT,"['PrimeCall', 'deltathree.com, Inc. (formerly known as Delta Three, Inc.)', 'RSL COM PrimeCall, Inc.', 'DeltaThree']","['October 1, 1999']",10-01-1999,[],New York,[],[]
EdietsComInc_20001030_10QSB_EX-10.4_2606646_EX-10.4_Co-Branding Agreement.pdf,CO-BRANDING AGREEMENT,"['Women.com', 'eDiets', 'WOMEN.COM NETWORKS, INC.', 'EDIETS.COM, INC.']","['May 22, 2000']",5/22/00,"['This agreement shall automatically renew for additional successive terms of twelve (12) months each at the end of the Initial Term (""Renewal Terms""), unless either party notifies the other in writing at least sixty (60) days prior to the end of the Initial Term.']",California,"['During the Term, eDiets will not buy, sell, display or distribute advertising from (including, but not limited to, banner ads, buttons, badges, text links, hyperlinks or editorial mentions) or otherwise promote any Women.com Compettive Company on any page of the eDiets Site that is within two clicks from the Gateway Page of the Diet Center.', 'For purposes of this Agreement, ""Competitive Company"" means any company that eDiets reasonably presents as, and Women.com reasonably agrees is, a direct competitor to eDiets by distributing on-line content principally relating to diets and diet counseling, including, but not limited to, Weight Watchers, Jenny Craig, NutriSystem, Nutrio, Asimba, DietSmart and uMagic.', 'For purposes of this Agreement, ""Women.com Competitive Company"" means any company that Women.com reasonably presents as, and eDiets reasonably agrees is, a direct competitor to Women.com by providing an on-line portal for women, including, but not limited to, Oxygen Media and iVillage,', 'Notwithstanding the foregoing, Women.com shall be entitled to (aa) provide mini and micro web sites and Women.com promotions and sponsorships to Jenny Craig; (bb) sell, display, or distribute advertisements, including banner advertisements, newsletter placements, internet radio, commerce placements and market research, or otherwise promote Competitive Companies on pages other than the Gateway Page of the Diet Center.', 'During the Term,<omitted>(b) eDiets will be the exclusive third party provider of content and interactive tools for diets and diet counseling to Women.com within the Diet Center;']",[]
MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.pdf,ENDORSEMENT LICENSING AND CO-BRANDING AGREEMENT,"['Endorser', 'collectively, Lender, Endorser, and Fitness are referred to as the ""AS Parties""', 'MusclePharm Corporation', 'Lender', 'Marine MP, LLC', 'Arnold Schwarzenegger', 'Fitness', 'collectively, ""MusclePharm"" or the ""Company""', 'Fitness Publications, Inc.']","['July 26, 2013']",7/26/13,"['If this Agreement is renewed for the Second Additional Term, then the Second Additional Term shall commence on July 23, 2019 and the Agreement shall expire and terminate automatically without further notice on July 22, 2022.', 'In the event that MusclePharm shall achieve Net Sales (as defined below) of $20 million (the ""First Renewal Threshold"") in the aggregate during the Third Contract Year, then this Agreement shall automatically be renewed for an additional term of three (3) years (the ""First Additional Term"") on the same terms and conditions for the Initial Term except that: (i) no additional Stock Compensation (as defined below) shall be issued in connection with the renewal Term, (ii) the Cash Compensation for the First Additional Term shall be as set forth in Section 7 and Exhibit ""C"" Section (2) attached hereto, (iii) Endorser shall only be obligated to make two (2) Appearances in each Contract Year during the First Additional Term pursuant to Section 4(a)(ii) below and (iv) the marketing budget to promote the Licensed Products shall be $5.0 million during each Contract Year of the First Additional Term (subject to Section 12(b) of this Agreement).', 'If this Agreement is renewed for the First Additional Term, then the First Additional Term shall commence on July 23, 2016, and the Agreement shall expire and terminate automatically without further notice on July 22, 2019.', 'In the event that MusclePharm shall achieve Net Sales of $50 million (the ""Second Renewal Threshold"") in the aggregate during the sixth Contract Year, then this Agreement shall automatically be renewed for an additional term of three (3) years (the ""Second Additional Term"") on the same terms and conditions for the initial Term except that: (i) no additional Stock Compensation (as defined below) shall be issued in connection with the renewal Term, (ii) the Cash Compensation for the renewal Term shall be as set forth in Section 7 and Exhibit ""C"" Section (3) attached hereto, (iii) Endorser shall only be obligated to make two (2) Appearances in each Contract Year during the Second Additional Term pursuant to Section 4(a)(ii) below and (iv) the marketing budget to promote the Licensed Products shall be $5.0 in each Contract Year of the Second Additional Term (subject to Section 12(b) of this Agreement).']",California,"[""During the term of this Agreement, or any extensions of this Agreement, Endorser and the Lender hereby agree and warrant that it will not enter into any other endorsement agreement for the use of Endorser's name, image and/or likeness for advertising, marketing and/or endorsement of any other dietary supplements during the Term of this Agreemen""]","['Notwithstanding the foregoing, in the event the expiration of this Agreement or termination of this Agreement by Musclepharm pursuant to paragraph 9(a), MusclePharm shall be entitled to sell-off the remaining Licensed Products for six (6) months after such expiration of this Agreement pursuant to paragraph 4(d) herein and shall continue to pay Endorser the Royalty set forth in paragraph 7 herein.', ""MusclePharm's obligations for the payment of a Royalty and the Guaranteed Minimum Royalty (as defined below) shall survive expiration or termination of this Agreement and will continue for so long as MusclePharm continues to manufacture, sell or otherwise market the Licensed Products."", 'During the Term, the right to use Endorser\'s Name and Appearance Rights granted to MusclePharm in this Section shall extend for six (6) months beyond the expiration of this Agreement (the ""Use-up Period"").', 'During the Term of this Agreement and during any sell-off period, MusclePharm shall pay Lender a royalty (the ""Royalty"") of 10% on Net Sales (as defined below) of Licensed Products sold through its wholesale Distribution Channels or retail Distribution Channels, as the case may be and 10% on Net Sales of the Training Video and any Products sold in connection with any Training Video as contemplated pursuant to the last sentence of Section 4(a)(i) above.', ""MusclePharm shall create no new advertising during the Use-up Period using Endorser's Name and Appearance, but shall have the right to use during the Use-up Period Endorser's Name and Appearance in advertisements and promotional materials created before the expiration date of this Agreement."", 'MusclePharm agrees to preserve and keep accessible and available to the AS Parties all relevant books and records for a period of at least three (3) years following the expiration or termination of the Agreement.']"
TomOnlineInc_20060501_20-F_EX-4.46_749700_EX-4.46_Co-Branding Agreement.pdf,CO-BRANDING AGREEMENT,"['Skype, Online BVI and the Company may be referred to individually as ""Party"" and collectively as ""Parties."" Skype, Online BVI, the Company, Skype Holding and Tom Holding may be referred to individually as ""party to this Agreement"" and collectively as ""parties to this Agreement.""', 'Skype', 'Tel-Online Limited', 'Online BVI', 'Skype Technologies, S.A.', 'TOM Online (BVI) Limited', 'Skype Communications, S.A.', 'Tom Holding', 'Company', 'TOM Online Inc.', 'Skype Holding']",['22nd day of August 2005'],8/22/05,"['This Agreement shall automatically continue following the Initial Term, for an additional period of three (3) years, unless a party to this Agreement provides written notice of termination to the other parties at least sixty (60) days prior to the expiration of the Initial Term or this Agreement (""Extended Term"" and, with the Initial Term, ""Term"").']","England, United Kingdom; Wales, United Kingdom",[],"['The Parties (including Online BVI on behalf of the Online Group) agree to maintain records (i) of all information reasonably necessary to verify all calculations to be made under Section 8.3.2, and (ii) supporting, verifying and necessary to demonstrate the calculation and collection of fees and/or revenue, as well as any deductions thereto, and payments made hereunder, including, without limitation, budgets, purchase orders, expense records, invoices, correspondence, banking and financial and other records pertaining to the determination of Gross Revenue, Direct Expenses and Adjusted Net Revenue, during the term of this Agreement and for a period of two (2) years following the expiration or termination hereof.', 'Each Party shall (i) immediately stop displaying, featuring, linking or in any other manner using the Company-Skype Branded Application (provided in the case of Skype, other than the Skype Software in the Company-Skype Branded Application), Company-Skype Toolbar, Company-Skype Branded Web Site, Company-Skype Branded Content, any co-branded materials or any other Intellectual Property of the other Parties (including, without limitation, Intellectual Property deemed to be owned by the other Parties under Section 4.2.3.2); (ii) return such materials directly to the other Parties, or delete and overwrite any electronically stored copies of such materials within thirty (30) days from the date of termination of this Agreement; (iii) within such thirty (30) day period, deliver to the other Parties a certificate duly executed by its authorised officer certifying its compliance with the foregoing, and (iv) provide the other Parties with such information and access to data and databases as may be necessary to permit such other Parties to fulfil any contractual obligations by them to users of the Company-Skype Branded Application undertaken by such other Parties prior to the time of termination.', 'The Parties agree that notwithstanding any termination or expiration of this Agreement, the rights and licenses granted to any Company- Skype Branded Customers prior to termination or expiration of this Agreement pursuant to any EULA shall continue during the 24 months after such termination or expiration for the sole purpose of permitting such users to continue to access and utilize the Company-Skype Branded Application and the Company-Skype Toolbar, and so long as any Gross Revenue is received with respect to the Company-Skype Branded Application and/or the Company-Skype Toolbar, the provisions of Section 5 shall continue to be applicable after any termination or expiration.']"
ConformisInc_20191101_10-Q_EX-10.6_11861402_EX-10.6_Development Agreement.pdf,DEVELOPMENT AGREEMENT,"['also known as Stryker Orthopaedics   (""Stryker"")', 'Conformis', 'Howmedica Osteonics Corp.', 'Conformis, Inc.', 'Stryker and Conformis are collectively referred to herein as the ""Parties"" and   individually as a ""Party.""']","['September 30, 2019']",9/30/19,[],New York,"['Except as specifically provided in the Distribution Agreement, Conformis shall be prohibited from   developing or assisting another in developing, or causing another to develop, Patient-Specific Instrumentation for Off-The-Shelf   Knee Implants for any Third Party in the field of orthopedics until January 1, 2032 (or earlier, to the extent set forth in Section   2.3.3.4 or Section 2.3.5 of the Distribution Agreement), with the exception that Conformis (including any entity involved in a   Change of Control of Conformis, any such entity an ""Acquirer""), may develop Patient-Specific Instrumentation for any Off-The-   Shelf Implants of Conformis, an Acquirer or any of their Affiliates.']",[]
EtonPharmaceuticalsInc_20191114_10-Q_EX-10.1_11893941_EX-10.1_Development Agreement.pdf,EXCLUSIVE LICENSE AND PRODUCT DEVELOPMENT AGREEMENT,"['Aucta Pharmaceuticals, Inc.', 'Eton Pharmaceuticals, Inc.', 'Aucta', 'ETON']","['June 12, 2019']",09-02-2019,[],Delaware,"['Aucta, for itself and its Affiliates, hereby grants to ETON in accordance with the terms and conditions of this Agreement, an exclusive (even as to and against Aucta in the Territory) right and license, including the right to sublicense, to the Products (or any components thereof), Dossiers, and all current and future Aucta Background Intellectual Property that is owned or controlled by Aucta or its Affiliates for ETON to develop, manufacture, import, use, promote, distribute, market, advertise, offer for sale or sell (collectively, ""Market"") the Products in and for the Territory.']","['In addition, within twenty-five (25) months after the termination or expiration of the Term and on a Product-by-Product basis, ETON shall perform a final ""true-up"" reconciliation and shall provide Aucta with a written report of such outlining the deductions specified in the definition of Net Sales.', ""After termination is effective and Aucta assumes control of the Product, ETON will provide, to the extent practicable, transition services to Aucta to include assistance with Product distribution, processing of rebates, drug safety, etc. at Aucta's cost for such services, for a reasonable period of time as mutually determined by the Parties but not to exceed one hundred eighty (180) days following termination so that Aucta can get its own such services in place."", ""If this Agreement is terminated by Aucta under Section 11.2 or 11.3, then (a) ETON shall have the right to, and Aucta shall hereby grant ETON a license to, Market or otherwise dispose of any existing inventory of any Products then in ETON's possession subject to paying all Royalties and other amounts due hereunder for such sales, (b) Aucta may keep all the payments under Section 6 paid by ETON up to the point of termination and for ETON's disposal of remaining inventory and Aucta is free to commercialize or relicense the Product with no further obligations owed to ETON, (c) ETON shall refrain from holding itself out as Aucta's distributor, in particular, eliminate any reference to the Product and Aucta from its business, trade style and promotional material, and (d) ETON shall transfer all rights, licenses within thirty (30) days of termination.""]"
FuelcellEnergyInc_20191106_8-K_EX-10.1_11868007_EX-10.1_Development Agreement.pdf,JOINT DEVELOPMENT AGREEMENT,"['FuelCell Energy, Inc.', 'FCE', 'ExxonMobil', 'ExxonMobil Research and Engineering Company']","['November 5, 2019']",10/31/19,[],New York,[],"['Such books, records and accounts will be maintained for a period of at least three (3) years following the termination or expiration of this Agreement, provided there are no pending disputes between the Parties.']"
ReedsInc_20191113_10-Q_EX-10.4_11888303_EX-10.4_Development Agreement.pdf,RECIPE DEVELOPMENT AGREEMENT,"['B C Marketing Concepts Inc., dba Full Sail Brewing Company', ""Reed's"", ""Reed's, Inc."", 'Company']","['October 11, 2019']",10-11-2019,[],New York,"['In exchange for Company\'s contributions and obligations under this Agreement, Reed\'s grants Company the exclusive right to manufacture, package, promote, sell and distribute the Products (if and to the extent approved by the Development Committee), subject to the terms and conditions of a separate Manufacturing and Distribution Agreement to be entered into by the parties concurrently with this Agreement, as it may be amended, modified, supplemented or restated from time to time (the ""Manufacturing and Distribution Agreement"").']",[]
GentechHoldingsInc_20190808_1-A_EX1A-6 MAT CTRCT_11776814_EX1A-6 MAT CTRCT_Distributor Agreement.pdf,DISTRIBUTOR AGREEMENT,"['XXXXXXXXXXXXXXXXXXXXX', 'Distributor', 'Company', 'B & C General Warehouse Corporation LLC']",['1 August 2019'],08-01-2019,['Distributor shall have the option to renew this Agreement for an additional Three (3) year period by providing prior written notice to Company within Ninety (90) days of the end of the initial period of this Agreement.'],Florida,"['Subject to the terms and conditions of this Distributor Agreement, Company hereby appoints and grants Distributor the exclusive right to sell and distribute the Products to customers that Distributor introduce and confirmed by Company, (in all territory of United State of America (USA) and to render other services as a distributor for Company as set forth herein.', ""Company shall not sell or otherwise supply, directly or indirectly, the Products to any Distributor's Customer's, except by sale through the Distributor.""]","['In the event that this Agreement is terminated or expires on its own terms, Company shall have no further responsibilities to Distributor except that in the event the Agreement terminates for any reason other than a breach hereof by Distributor, Company shall be obligated to process orders accepted by Company prior to the effective date of such termination or expiration or within Ninety (90) days thereafter.']"
ImineCorp_20180725_S-1_EX-10.5_11275970_EX-10.5_Distributor Agreement.pdf,NON-EXCLUSIVE DISTRIBUTOR AGREEMENT,"['SUNWAI Technology', 'Distributor', 'iMine Corporation', 'JRVS']",['19th day of July 2018'],7/19/18,[],Indiana,[],[]
WaterNowInc_20191120_10-Q_EX-10.12_11900227_EX-10.12_Distributor Agreement.pdf,EXCLUSIVE DISTRIBUTOR AGREEMENT,"['Distributor', 'Hydraspin and Distributor are sometimes hereinafter referred to individually as a ""Party"" and collectively as the ""Parties.""', 'the ""Subsidiary,"" and collectively with Water Now, ""Hydraspin"")', 'Hydraspin USA, Inc.', 'WATER NOW, INC.', 'BESTEV MANAGEMENT, LLC', 'Water Now']","['12th day of November, 2019']",11-12-2019,"['Upon expiration of the Initial Term of this Agreement, this Agreement will automatically renew for additional, successive five (5) year periods unless either Party provides the other Party written notice of its desire to terminate at least one hundred twenty (120) days prior to the end of the Initial Term or any renewal.']",Texas,"[""Hydraspin hereby grants to Distributor an exclusive non-transferable and royalty-free right and license to use Hydraspin's Marks in connection with the advertising, promotion, marketing, distribution and sale of the Products in the Territory in accordance with Hydraspin's standards and instructions"", 'Distributor shall be entitled to advertise, promote, market or<omitted>solicit any Customers that have a business presence outside the Territory, except that Distributor shall not conduct solicitation activities in any outside territory where Hydraspin is bound to an exclusive distributor agreement with a third party, provided that Hydraspin has notified Distributor in writing of its arrangements with the other distributor and of the territory which is subject to exclusivity in favor of the other distributor.', 'If this Agreement is extended beyond the Initial Term, as hereinafter defined, the number of Customer Locations to be secured to maintain exclusivity during the pendency of the Agreement shall be increased to 50 from 25.', ""Hydraspin hereby appoints Distributor, and Distributor hereby accepts appointment, as Hydraspin's exclusive distributor of the Products in the Territory during the term of this Agreement, subject to the terms and conditions of this Agreement, including, but not limited to, the satisfaction of the Performance Benchmarks."", 'Hydraspin certifies, stipulates, and agrees that the Hydraspin will deal exclusively with and through the Distributor in relation to the distribution of the Products in the Territory', 'In the event the Distributor loses exclusivity on a territory due to not meeting Performance Benchmarks, the Distributor shall maintain exclusivity on any and all existing Products that are in the field and operating at them time exclusivity if forfeited.']",[]
EcoScienceSolutionsInc_20171117_8-K_EX-10.1_10956472_EX-10.1_Endorsement Agreement.pdf,ENDORSEMENT AGREEMENT,"['Eco Science Solutions, Inc.', 'Stephen Marley', 'Talent', 'ESSI']",['14th day of November 2017'],11/14/17,"['The term of this Agreement shall be for one (1) year commencing on the Effective Date and automatically renewing annually thereafter, unless either party provides a thirty-day notice of written termination one to the other (""Term"").']",Michigan,[],[]
NakedBrandGroupInc_20150731_POS AM (on S-1)_EX-10.75_9196027_EX-10.75_Endorsement Agreement.pdf,COLLABORATION & ENDORSEMENT AGREEMENT,"['Wade Enterprises, Athlete and together with Naked, are each referred to herein as a ""Party"" and collectively, the ""Parties"".', 'Naked', 'Athlete', 'Wade Enterprises', 'The Naked Brands Group, Inc.', '""Athlete"" and together with Wade Enterprises, collectively ""Wade"")', 'Wade Enterprises, LLC', 'f/s/o Dwyane Wade']","['15th day of June, 2015']",6/15/15,"['In the event that either Wade or Naked wishes to extend the Term of the Agreement as contemplated above, it shall provide the other Party with written notice at least ninety (90) days prior to the expiration of the Term.', 'The other Party will then have a period of fourteen (14) days from the date of the notice to indicate whether it also desires to extend the Term, on the terms and conditions set forth herein and if no such indication is made, the other Party will be deemed to have declined the offer to extend', 'The initial term of this Agreement shall be for a period of four (4) years, commencing on the Effective Date, which term may be extended for up to three (3) years by written agreement of both Parties prior to the expiration date of the initial term or any extension thereof (collectively, the ""Term"").']",New York,"['Notwithstanding the foregoing, Wade agrees that for a period of ninety (90) days prior to the expiration of the Term (unless the Agreement is terminated by Wade as permitted hereunder), Naked shall have the exclusive right to negotiate for continued endorsement by Athlete of the Naked Products.', 'During the Term and subject to the limitations set forth in this Agreement, Naked shall have an exclusive right and license in the Territory to use Athlete\'s name, nickname, initials, autograph, image, likeness, photographs, biographical details, facsimile signature, voice, videos, electronic media depictions, any words, symbols or other depictions, as well as any other identifying attributes that would identify Athlete to the public, including any trade mark(s), copyrights which Wade has, as set forth on Schedule A attached hereto, and all multimedia assets that Wade owns or has right to use (collectively, the ""Wade Image"") solely for the advertising, endorsement, promotion, or sale of the Naked Products (including the Wade Products) in the Territory as follows:']","['For a period of six (6) months at the end of the Term (the ""Sell-off Period""); provided that the Agreement was not terminated by Wade as permitted herein, Naked will have the right to continue to sell the Wade Products (defined below) for which orders have already been placed at the end of the Term on the terms and conditions herein.']"
SimplicityEsportsGamingCompany_20181130_8-K_EX-10.1_11444071_EX-10.1_Franchise Agreement.pdf,MASTER FRANCHISE AGREEMENT,"['Franchisor', 'Smaaash Entertainment Private Limited', 'I-AM Capital Acquisition Company', 'Franchisee']","['20t h day of November, 2018']",11/20/18,[],New York,"['Except as provided in the next sentence, the license granted herein shall be exclusive.', '""Exclusivity"" shall mean that Franchisor shall not grant any further licenses to third parties in the Trademarks for use in connection with Smaaash Centres in the Territory, and the Franchisee shall not enter into any arrangement or agreement with any third parties for establishing or operating any gaming and entertainment centres identical or similar to Smaaash Centres, in the Territory except as otherwise provided in this Agreement; provided, however, that Franchisor may continue to use the Trademarks in the Territory in connection with the operation of Franchisor\'s entertainment centers already set up as of the Effective Date in the Territory. The restriction contained in this Agreement shall apply on the parties throughout the Term.', 'Subject to Section 1.2, Franchisor hereby grants to Franchisee the exclusive right, (a) to establish and operate Smaaash Centres in the Territory, (b) to sub-license the right to establish and operate Smaaash Centres to third party franchisees in and for the Territory, (c) a license to use the products and other services developed by Franchisor with respect to the Smaaash Centres (including a right to authorise the use of products and services developed by the Franchisor by third party franchisees), in the Territory, and (d) to identify third party franchisees for the Smaaash Centres in the Territory.']",[]
PareteumCorp_20081001_8-K_EX-99.1_2654808_EX-99.1_Hosting Agreement.pdf,MOBILE VIRTUALNETWORK ENABLER HOSTING AGREEMENT,"['each individually referred to as ""Party"" and together as ""Parties"".', 'Elephant Talk Communication Holding AG', 'T-Mobile', 'T-Mobile Netherlands B.V.', 'ELEPHANT TALK']",['18/9/2008'],9/18/08,"['At the end of *** Parties will negotiate in good faith regarding a possible extension of the Initial Term.', 'Parties can mutually agree in writing to deviate from an automatic extension of *** by extending this Agreement for a longer period than ***.', 'If no termination notice is provided, the Agreement will be automatically extended for consecutive *** periods until such time as *** termination notice is provided.']",Netherlands,[],[]
VitalibisInc_20180316_8-K_EX-10.2_11100168_EX-10.2_Hosting Agreement.pdf,SERVICES AND HOSTING AGREEMENT,"['VITALIBIS INC', '-Licensee""', 'VOTOCAST, Inc.', '""VOTOCAST']",['3-14-18'],3/14/18,"['This Agreement shall automatically renew beyond the Initial Term for successive one (I) year terms (each, a ""Renewal Term""), unless a Party provides the other with written notice of termination at least one hundred eighty (180) days prior to the expiration of the Initial Term or the then-current Renewal Term.']",California,[],[]
QuantumGroupIncFl_20090120_8-K_EX-99.2_3672910_EX-99.2_Hosting Agreement.pdf,e-business Hosting Agreement,"['IBM', 'The Quantum Group Inc.', 'Customer', 'International Business Machines Corporation']",[],12-03-2008,[],New York,[],[]
GarrettMotionInc_20181001_8-K_EX-2.4_11364532_EX-2.4_Intellectual Property Agreement.pdf,"INTELLECTUAL PROPERTY AGREEMENT, d","['HONEYWELL INTERNATIONAL INC.', 'GARRETT MOTION INC.', 'SpinCo', 'Honeywell']","['September 27, 2018']",9/27/18,[],New York,[],[]
ArtaraTherapeuticsInc_20200110_8-K_EX-10.5_11943350_EX-10.5_License Agreement.pdf,SPONSORED RESEARCH AND LICENSE AGREEMENT,"['University', 'ArTara', 'ArTara, Inc.', 'The University of Iowa']","['November 28, 2018']",11/28/18,[],Iowa,"['University hereby grants to ArTara an exclusive Right of Reference to all Program Regulatory Filings by University in support of the Product.', 'University hereby grants to ArTara an exclusive license to use the Program Data solely for the Project and in Regulatory Filings in the Field in the Territory.']","['Upon termination of the Project by ArTara this Agreement will terminate subject to Section 8.3 and ArTara will reassign to University the IND if assignment thereof previously occurred pursuant to Section 4.3.', 'In the event of any termination of the Project by University, (a) University agrees to complete Phase I and II of the Project, and (b) ArTara will continue to provide annual funding until the completion of Phase II.']"
CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_License Agreement.pdf,COMMERCIALIZATION AND LICENSE AGREEMENT,"['Vyera', 'CytoDyn Inc.', 'Vyera Pharmaceuticals, LLC', 'CytoDyn', 'CytoDyn and Vyera are sometimes referred to herein individually as a ""Party"" and collectively as the ""Parties.""']","['December 17, 2019']",12/17/19,[],New York,"['In the event that such assignment would be unlawful, Vyera shall, and hereby does, grant to CytoDyn an exclusive, irrevocable, worldwide, sublicensable (including through multiple tiers), transferrable (without consent) royalty free license to any and all right, title and/or interest that it may have in or to an Invention.', ""Without limiting the foregoing, Vyera shall have the exclusive right and responsibility throughout the Territory for the following: (a) receiving and accepting orders for the Licensed Product from customers; (b) distributing the Licensed Product to customers; (c) controlling invoicing and collection of accounts receivable for Licensed Product sales; (d) recording Licensed Product sales in its books of account for sales (in accordance with Vyera's accounting standards consistently applied (currently GAAP)); (e) subject to Section 5.5, determining pricing for the Licensed Product and all aspects of the promotion (including promotional materials) to be used in Commercializing Licensed Products; (f) negotiating with Third Parties, including without limitation, payors, pharmacy benefit managers and distributors, with respect to sales and distribution of Licensed Product; and (g) paying all rebates, chargebacks and other amounts due to customers in respect of Licensed Products (it being understood that all such amounts shall be deducted in calculating Net Sales)."", 'Vyera shall purchase all of its requirements for supply of Licensed Product exclusively from CytoDyn in accordance with the terms and conditions of the Supply Agreement.', 'CytoDyn hereby grants to Vyera, and Vyera hereby accepts, an exclusive royalty-bearing license (or sublicense, as the case may be), under the CytoDyn Patents, the CytoDyn Know-How and the Inventions (if any) solely to Commercialize, use, have used, offer for sale and sell Licensed Products in the Field in the Territory.']","['In the event of a termination by Vyera under Section 11.2, the following terms shall apply: (i) at CytoDyn\'s request, the Parties will negotiate in good faith a transition services agreement (the ""Transition Services Agreement""), under which Vyera will provide certain Commercialization services to CytoDyn in connection with CytoDyn efforts to Commercialize the Licensed Product in the Field in the Territory; (ii) the services to be provided by Vyera pursuant to the Transition Services Agreement (the ""Transition Services"") will be negotiated in good faith taking into account (A) the activities undertaken by Vyera in connection with the Commercialization of Licensed Product during the Term and (B) Vyera\'s then-existing resources and capabilities (it being understood and agreed that Vyera shall not (x) be required to hire any new employees or enter into any new agreements with Third Parties in order to provide the Transition Services or (y) terminate any employee or agreement the primary purpose of which is to circumvent its obligations to provide the Transition Services); (iii) the Transition Services Agreement will require Vyera to provide Transition Services for a period of up to six (6) months from the effective date of termination; provided that CytoDyn will have the ability to terminate Transition Services on a service-by-service basis as they are transitioned; and (iv) Transition Services will be reimbursed at Vyera\'s actual cost plus ten percent (10%) by CytoDyn. (v) At CytoDyn\'s reasonable request and subject to the terms of the applicable agreement, Vyera will use its reasonable best efforts to assign to CytoDyn any Third Party agreements that relate to the Transition Services matters solely for Licensed Product in the Territory in the Field.']"
VirtuosoSurgicalInc_20191227_1-A_EX1A-6 MAT CTRCT_11933379_EX1A-6 MAT CTRCT_License Agreement.pdf,NON-EXCLUSIVE LICENSE AGREEMENT- FOR SALES,"['Virtuoso Surgical, Inc.', 'The Johns Hopkins University', 'Company', 'JHU']","['May 3, 2016']",05-11-2016,[],Maryland,[],[]
AtnInternationalInc_20191108_10-Q_EX-10.1_11878541_EX-10.1_Maintenance Agreement.pdf,Network Build and Maintenance Agreement ,"['AT&T Mobility LLC', 'Commnet Wireless, LLC', 'each of which may be referred to in the singular as a ""Party"" or in the plural as the ""Parties.""', 'Vendor', 'AT&T']","['31  day of July, 2019']",7/31/19,[],New York,[],"[""Upon expiration or termination of this Agreement, but prior to the effectiveness of full termination of the Agreement, AT&T may exercise any rights and remedies available to AT&T under this Agreement, at law or in equity, including AT&T's right to exercise any one or more of the Termination Remedies set forth in the Build Addendum, and Vendor shall, upon the request and at the expense (other than termination in accordance with Subsection (c) hereof) of AT&T:<omitted>(ii) provide reasonable assistance as may be necessary for the orderly, non-disrupted continuation of the Services, (iii) transfer all of the contracts related to the Cell Sites to AT&T<omitted>as contemplated in the Build Addendum and (iv) reimburse AT&T for any AT&T Provided Equipment or other assets that are not installed at a Cell Site and cannot be returned in good working order (based on the acquisition costs plus taxes and shipping costs)."", 'Vendor will maintain and retain the records set forth in Subsection (a) during the term of the Agreement and for three (3) years thereafter (unless a discovery or legal hold request is made with respect to such records, in which case Vendor shall retain such records until AT&T notifies Vendor that such discovery or legal hold request has expired)', ""Vendor shall, at AT&T's option, return to AT&T, or hold for AT&T's disposition, any or all of such material provided by AT&T under this Agreement upon termination of this Agreement or the withdrawal of the material furnished; provided however, that with respect to any scrap produced as a by-product remaining in Vendor's possession at the completion of all Work to be provided at a Cell Site, Vendor shall, at AT&T's option, return to AT&T, or hold for AT&T's disposition, such scrap material for a period of one hundred twenty (120) days following the earlier of Location""]"
InmodeLtd_20190729_F-1A_EX-10.9_11743243_EX-10.9_Manufacturing Agreement.pdf,TURN - KEY MANUFACTURING AGREEMENT,"['FLEXTRONICS ISRAEL LTD.', 'INVASIX LTD.', 'Customer', 'Contractor.']",[],04-01-2011,"['This Agreement shall automatically be renewed for successive one (1) year increments unless either party request in writing, at least ninety (90) days prior to the anniversary date, that this Agreement not to be renewed.']",Israel,[],"['In the event of termination of this Agreement or a cancellation of a Purchase Order, and/or discontinuance of a Product, or excess materials created by an Engineering Change, Customer agrees to compensate Contractor for unused material inventory which are affected by such termination, cancellation or discontinuance']"
NeuroboPharmaceuticalsInc_20190903_S-4_EX-10.36_11802165_EX-10.36_Manufacturing Agreement_ Supply Agreement.pdf,MANUFACTURING AND SUPPLY AGREEMENT (DA-9801 Licensed Products),"['Dong-A', 'NeuroBo', 'Dong-A ST Co., Ltd.,', 'NeuroBo Pharmaceuticals, Inc.,']","['September 28, 2018']",9/28/18,[],New York,[],[]
UpjohnInc_20200121_10-12G_EX-2.6_11948692_EX-2.6_Manufacturing Agreement_ Supply Agreement.pdf,MANUFACTURING AND SUPPLY AGREEMENT,"['Manufacturer', 'Upjohn Inc.', 'Customer', 'Manufacturer and Customer may be referred to herein individually as a ""Party"" or collectively as the ""Parties"".', 'Pfizer Inc.']",['[‚óè]'],[]/[]/[][],"['A Facility Addendum may be extended for up to three (3) additional periods of twelve (12) months (each, an ""Extension Period"") by written notice given by Customer to Manufacturer not less than twelve (12) months prior to the expiration of the Initial Term or the applicable Extension Period, as the case may be', 'Unless otherwise provided in the applicable Facility Addendum, this Agreement (a) shall commence on the Effective Date and shall continue for a period of four (4) years from such date (the ""Initial Term"" of this Agreement), unless sooner terminated pursuant to Section 7.3, 7.4, 7.5, 7.6 or 7.7, and (b) may be extended for up to three (3) additional periods of twelve (12) months (each, an ""Extension Period"") by written notice given by Customer to Manufacturer not less than twelve (12) months prior to the expiration of the Initial Term or the applicable Extension Period, as the case may be.']",Delaware,"['During the Exclusivity Period, on a Product SKU-by-Product SKU and country-by-country basis within the applicable Territory, Customer shall purchase from Manufacturer, in accordance with the terms and conditions of this Agreement, at least the Exclusive Purchase Requirement of its requirements for such Product SKU in such country; provided, however, that In-Flight or Shared Volume Products shall be excluded from the exclusivity requirements set forth in this Section 2.1(e)(i).', '""Exclusive Purchase Requirement"" means, on a Product SKU-by-Product SKU and country-by country basis within the applicable Territory, (a) in the first two (2) years of the Initial Term, one hundred percent (100%) of Customer\'s total requirements for such Product SKU and (b) in the third (3rd) year of the Initial Term, fifty percent (50%) of Customer\'s total requirements for such Product SKU; provided, however, that (x) such quantities of Product reasonably procured by Customer to qualify a back-up supplier for such Product shall be excluded from the Exclusive Purchase Requirement, and (y) for the avoidance of doubt, Customer may commercialize such quantities of Product procured under (x) above without violating the applicable Exclusive Purchase Requirement or related provisions in Section 2.1(e).', 'In the event of a Triggering Event, Customer\'s Exclusive Purchase Requirement with respect to each and every Product that is the subject of the Triggering Event shall be temporarily suspended until such time as Manufacturer notifies Customer that Manufacturer is able to resume the manufacture and supply of the subject Product(s) on the terms and conditions of this Agreement (such period referred to as the ""Exclusive Purchase Requirement Suspension Period""); provided that, (i) during such Exclusive Purchase Requirement Suspension Period, Customer shall use commercially reasonable efforts to limit its orders for the subject Product(s) to the quantities specified in the last Forecast that preceded the Triggering Event for the applicable period(s) and promptly notify Manufacturer in the event and to the extent that Customer\'s orders exceed such quantities specified in such Forecast and (ii) Customer shall be entitled to take delivery of Product(s) ordered during the Exclusive Purchase Requirement Suspension Period even if such delivery is scheduled for or actually occurs subsequent to the Exclusive Purchase Requirement Suspension Period.', 'Following the Exclusivity Period (and during the Exclusivity Period, with respect to Product SKU quantities in excess of the Exclusive Purchase Requirement in accordance with the preceding sentence), nothing in this Agreement shall prevent Customer or any of its Affiliates from manufacturing Product for itself, or having Product manufactured by a Third Party, including in amounts in addition to the Purchase Orders for Product issued to Manufacturer in accordance with this Agreement.']","['Upon termination of this Agreement by Customer in whole or in part or upon the termination of any Facility Addendum, in each case, pursuant to Section 7.3, 7.4, 7.5 or 7.6, and on a terminated-Product-by-terminated-Product basis, at Customer\'s option and pursuant to Customer\'s instructions, Manufacturer shall provide Customer with sufficient inventory of such terminated Product to ensure business continuity according to then-current terms and pricing (subject to Section 3) until the earlier of: (i) Customer\'s identification of, and securing of Regulatory Approval for, another supplier of such terminated Product or (ii) unless otherwise set forth in the applicable Facility Addendum as the ""Inventory Tail Period"" for such Product, a time period that reflects Customer\'s reasonable needs of such Product as mutually agreed upon by the Parties in good faith.', 'In the event of the expiration of this Agreement or termination of this Agreement in whole or in part (including the termination of any Facility Addendum) by Customer in accordance with Section 7.3, 7.4, 7.5 or 7.6, Customer may, at its option within ninety (90) days immediately following the effective date of the expiration or termination of this Agreement, purchase any work in process and/or Product Materials that Manufacturer has purchased exclusively for Customer in accordance with this Agreement for the production of any terminated Product.', ""Any Product quarantined at the time of expiration or termination of this Agreement shall be disposed of or destroyed by Manufacturer in accordance with Customer's instructions and at Customer's cost; provided that, to the extent (i) such quarantine is the result of Manufacturer's gross negligence, fraud, willful misconduct or breach of this Agreement or (ii) this Agreement is terminated in whole or in part with respect to such Product (including the termination of the applicable Facility Addendum) by Customer in accordance with Section 7.3, 7.4, 7.5 or 7.6, then Manufacturer shall be responsible for all costs incurred by Manufacturer in connection with disposing and destroying such quarantined Product."", ""The Parties shall reasonably cooperate and mutually agree to facilitate the provision of any additional reasonable Technical Support with respect to the applicable Product or Products to Customer, including assistance through the transfer process, Manufacturer Personnel visits to the Receiving Site and training and troubleshooting during the Receiving Site's first production run of the applicable Product or Products, in each case, as and to the extent reasonably agreed by Manufacturer in each instance (and subject to Sections 2.10(d), 2.10(e) and 2.10(f))."", ""In the event of the termination of this Agreement by Customer in accordance with Section 7.7 or the termination of this Agreement by Manufacturer in accordance with Section 7.3, 7.4, 7.5 or 7.6, Customer shall purchase at cost all Product Materials purchased in accordance with Customer's Purchase Orders and on reasonable reliance upon Customer's Forecast; provided that Manufacturer uses its reasonable commercial efforts to exhaust existing stocks of such Product Materials prior to the date of<omitted>termination."", 'In the event that Manufacturer or any of its Affiliates, directly or indirectly, sells, assigns, leases, conveys, transfers or otherwise disposes of any Facility (a ""Facility Disposition""), then Manufacturer shall immediately notify Customer of such event and Customer shall be entitled for a period of six (6) months after the receipt of such notice to terminate any Facility Addendum with respect to such Facility for cause immediately upon written notice to Manufacturer and, in the event Customer decides not to terminate the Facility Addendum for cause, Customer shall be entitled for a period of two (2) years (or such longer period in order to obtain approval for manufacture from all applicable Governmental Authorities) after<omitted>receipt of such notice to receive Technical Support at Manufacturer\'s sole cost to enable Customer to orderly transfer production of affected Product or Products to a Customer facility or an alternative facility as designated by Customer; provided that Manufacturer shall notify Customer of any proposed or planned Facility Disposition by Manufacturer or any of its Affiliates as soon as reasonably practicable and in any event no later than the date that is three (3) months prior to the effective date of such Facility Disposition.', ""Upon termination or expiration of this Agreement in whole or in part or any Facility Addendum, if requested by Customer within ninety (90) days immediately following the effective date of such expiration or termination of this Agreement and pursuant to Customer's reasonable request and instructions, Manufacturer shall use commercially reasonable efforts to, as applicable, make assignments or partial assignments of such material contracts, licenses, permits, and other material documents, as applicable, in each case subject to any restrictions on assignment, or as may otherwise be set forth in any Contract relating thereto.""]"
CcRealEstateIncomeFundadv_20181205_POS 8C_EX-99.(H)(3)_11447739_EX-99.(H)(3)_Marketing Agreement.pdf,WHOLESALE MARKETING AGREEMENT,"['S2K', 'S2K Financial LLC', 'Distributor', 'ALPS Distributors, Inc.']",['24t h day of August 2018'],8/24/18,[],Colorado,[],[]
EmmisCommunicationsCorp_20191125_8-K_EX-10.6_11906433_EX-10.6_Marketing Agreement.pdf,LOCAL PROGRAMMING AND MARKETING AGREEMENT (WQHT HD2),"['MediaCo Holding Inc.', 'Programmer', 'Licensee', 'WBLS-WLIB LLC']","['November 25, 2019']",11/25/19,[],Indiana,[],[]
TodosMedicalLtd_20190328_20-F_EX-4.10_11587157_EX-4.10_Marketing Agreement_ Reseller Agreement.pdf,MARKETING AND RESELLER AGREEMENT,"['Care G. B. Plus Ltd.', 'Todos Medical Ltd.', 'Todos', 'Reseller']",['20t h day of December 2018'],12/20/18,"['Upon completion of the Initial Term, provided that the Reseller has achieved the Annual Milestones, the term of the Agreement shall be automatically renewed for an additional five (5) years.', 'Thereafter, at the end of each renewal term, the Agreement shall renew for an additional two (2) years unless one party provides the other party with prior written notice of non-renewal at least sixty (60) days prior to the expiration of the then-current term.']",Israel,"['Subject to the terms and conditions of this Agreement, Todos hereby grants the Reseller a non-sublicensable, non-transferable, exclusive right to distribute and sell the Products to Customers in the Territory; provided, however, that Reseller may sub-license or transfer its distribution rights to a subsidiary or affiliate of the Reseller.']","['During the term and for a period of three (3) years following the termination or expiration of this Agreement, the Reseller shall maintain complete books of accounts and records consistent with sound business and accounting principles and practices consistently applied.']"
VertexEnergyInc_20200113_8-K_EX-10.1_11943624_EX-10.1_Marketing Agreement.pdf,JOINT SUPPLY AND MARKETING AGREEMENT,"['Vertex Energy Operating, LLC', 'Bunker One (USA) Inc.', 'Vertex', 'Bunker One']","['10t h day of January, 2020']",05-01-2020,"['The term of this JSMA shall commence on May 1, 2020 (the ""Commencement Date"") and ends at April 30, 2029 (the ""Term""), with automatic renewals each for a period of five (5) years (a ""Renewal Term"") unless notice is given pursuant to 5.2.']",Alabama,"['During the Term, neither Vertex nor any affiliate of Vertex may sell any Product to any customers for their use as bunker fuel other than pursuant to the terms of this JSMA.', 'It is agreed that only Bunker One will be marketing this JSMA and the JSMA Output towards various customers, but if a Party receives a Nomination (being a written or oral request by/from a customer to a Party stating delivery place, delivery date and window etc.) or any other communication from a customer regarding the supply of Product (either spot or whole cargo) in the Area, the Party is obliged to forward the Nomination to Bunker One and refer the customer to Bunker One.', 'All sales towards customers for bunker fuel will be carried out exclusively by Bunker One in accordance to the terms set forth herein.', 'All sales towards customers for bunker fuel will be carried out exclusively by Bunker One in accordance to the terms set forth herein. As such all communication with customers shall go via Bunker One unless otherwise is specific written agreed in advance.']",['In the event of a termination in accordance to clause 5.2 it is agreed that both parties agree to unwind and minimize costs and exit the JSMA as soon as practicably possible not exceeding 120 days.']
XpresspaGroupInc_20190401_10-K_EX-10.28_11599457_EX-10.28_Marketing Agreement.pdf,PRODUCT SALE AND MARKETING AGREEMENT,"['Calm.com, Inc.,', 'Each of Calm and XSPA may be referred to herein individually as a ""Party"" and collectively as the ""Parties"".', 'Calm', 'XpresSpa Group, Inc.', 'XSPA']","['12th day of November, 2018']",11-12-2018,"['Following the Initial Term, this Agreement shall automatically renew for successive terms of six (6) months (each a ""Renewal Term"", and together with the Initial Term, the ""Term"") unless written notice is given by either Party no later than thirty (30) days in advance of the expiration of the Initial Term or the applicable Renewal Term.']",New York,"['Throughout the Term and for a period of six (6) months after the expiration or termination of this Agreement, neither XSPA nor any of its affiliates shall, directly or indirectly, sell, offer for sale, market or promote any digital meditation or digital sleep products (other than the Products), including online or in any Store in the Territory, without the express prior written consent of Calm.', 'Throughout the Term and for a period of six (6) months after the expiration or termination of this Agreement, neither Calm nor any of its affiliates shall, directly or indirectly, sell, offer for sale, market or promote any digital meditation or digital sleep products in any retail location located in an airport other than in collaboration with XSPA, without the express prior written consent of XSPA.']","[""Upon termination or expiration of this Agreement, Calm (at its sole expense) may engage a third party to audit XSPA's inventory of any and all Product Collateral then on hand at each Store and XSPA shall promptly return or dispose of such inventory as instructed by Calm at Calm's sole expense."", 'Throughout the Term and for a period of six (6) months after the expiration or termination of this Agreement, Calm shall have a right of first refusal to expand the rights and obligations described in this Agreement to any Stores outside the Territory (the ""ROFR"").', 'If any such insurance is on a ""claims made"" basis, XSPA shall maintain coverage thereunder for a period of at least two (2) years following the termination of this Agreement.', 'In addition, if Calm does not provide XSPA with instructions within twenty (20) days of the termination or expiration of this Agreement, XSPA shall be permitted to dispose of any inventory of any and all Product Collateral then on hand at each Store.']"
FerroglobePlc_20150624_F-4A_EX-10.20_9154746_EX-10.20_Outsourcing Agreement.pdf,OUTSOURCING AGREEMENT,"['the Customer', 'ESPACIO INFORMATION TECHNOLOGY, SA.', 'EIT', 'SILICON SMELTERS << Pty >> Ltd']","['1st day of January, 2009,']",01-01-2009,['It is established by calendar year and renewed tacitly every year.'],Spain,[],[]
ExactSciencesCorp_20180822_8-K_EX-10.1_11331629_EX-10.1_Promotion Agreement.pdf,COLOGUARD¬Æ PROMOTION AGREEMENT,"['Exact', 'Exact Sciences Corporation', 'Pfizer and Exact may each be referred to herein individually as a ""Party"" and collectively as the ""Parties"".', 'Pfizer', 'Pfizer Inc.']","['August 21, 2018']",8/21/18,[],New York,"['Subject to compliance by Pfizer with the terms of this Section 3.2(d), during the Term, Exact agrees (A) not to enter into any new binding arrangement with any media vendor for Advertising of the Product without the written consent of Pfizer, which consent shall not be unreasonably withheld, (B) not to meet with any advertising agency or media vendor to discuss any Advertising proposals for content development and creative direction of the Product, without providing Pfizer with a reasonable opportunity for a representative of Pfizer present and participate and (C) to promptly inform Pfizer if it enters into any arrangement with any advertising agency with respect to the Product.', 'Commencing on the Launch Date, Exact and its Affiliates hereby grant to Pfizer and its Affiliates, on an exclusive basis for the Co-Promote Field (except as to Exact and its Affiliates), and Pfizer accepts, the right and obligation to Promote and Detail the Product in the Territory during the Term jointly with Exact, in accordance with the terms and conditions of this Agreement, all Applicable Laws and the applicable Annual Marketing Plan.']","['Exact shall use commercially reasonable efforts to provide six (6) month notice prior to the expiry of the Term, or in the case of termination by Pfizer under Section 8.4, within the applicable notice period in advance of the effective date of such termination, that Exact intends for Pfizer to continue providing Advertising services for the Product pursuant to Section 3.2(d).', 'After the expiration of the Term or termination pursuant to Section 8.4 by either Party or Section 8.6 by Exact, based on cumulative Incremental Laboratory Services Revenue achieved during the Term or up to the termination date, Exact agrees to pay Pfizer the applicable royalty payment set forth below for twelve (12) consecutive Calendar Quarters following the expiration of the Term (the ""Tail Period""); provided, however, the Tail Period shall be reduced to the number of full Calendar Quarters completed during the Term if less than twelve (12) Calendar Quarters if either Party terminates the Agreement without cause pursuant to Section 8.4 or Exact terminates as a result of a Change of Control pursuant to Section 8.6.']"
DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement.pdf,CO-PROMOTION AGREEMENT,"['Dova Pharmaceuticals, Inc.', 'Dova', 'Valeant Pharmaceuticals North America LLC', 'Valeant', 'Dova and Valeant are each referred to individually as a ""Party"" and together as the ""Parties"".']","['September 26, 2018']",9/26/18,[],[* * *],"['During the Term, subject to the terms and conditions of this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis (solely with Dova and its Affiliates), to Detail and promote the Product in the Specialty in the Territory in the Field, and to conduct the Valeant Activities and the activities of the institutional account management team (pursuant to and subject to the terms of Section 4.1.5) for the Product in the Territory in the Field in accordance with the terms and conditions of this Agreement.']",[]
VnueInc_20150914_8-K_EX-10.1_9259571_EX-10.1_Promotion Agreement.pdf,PROMOTION AGREEMENT,"['Promoter', 'BookingEntertainment.com', 'VNUE, Inc.', 'VNUE']","['September 10, 2015']",09-10-2015,"['At any time prior to the end of the Term, the Parties may agree in writing to extend the Agreement for successive One (1) Year periods (the ""Renewal Terms"") under the same conditions set forth herein.']",Nevada,[],[]
SigaTechnologiesInc_20190603_8-K_EX-10.1_11695818_EX-10.1_Promotion Agreement.pdf,PROMOTION AGREEMENT,"['MMT', 'SIGA', 'SIGA and MMT are sometimes referred to individually as a ""Party"" and collectively as the ""Parties"". RECITALS', 'MERIDIAN MEDICAL TECHNOLOGIES, INC.', 'SIGA TECHNOLOGIES, INC.']","['May 31, 2019']",5/31/19,"['This Agreement shall be automatically renewed for successive three (3) year terms thereafter (each a ""Renewal Term"" and together with the Initial Term, the ""Term"") until and unless (i) either Party provides the other Party written notice of non-renewal no later than ninety (90) days prior the end of the Initial Term or any Renewal Term or (ii) earlier terminated as provided in this ARTICLE 11.']",New York,"['As of the Effective Date, there are no rights with respect to the Product or the SIGA Trademarks in the Territory granted by SIGA, in each case, to any Person or entity other than MMT;', 'Subject to the terms and conditions of this Agreement, SIGA hereby grants to MMT an exclusive right and license, with the right to grant sublicenses as permitted under Section 2.1(b), under the SIGA Intellectual Property solely to Promote the Product in the Field in the Territory.', 'The license granted by SIGA to MMT under this Section 2.1(a) will be exclusive even as to SIGA with respect to rights to Promote the Product in the Field in the Territory, except as set forth in Section 2.4 below.']","['Upon termination of this Agreement pursuant to this ARTICLE 11, for all Customer Contracts then in force in the Territory, MMT shall either (i) promptly exercise its rights to terminate such Customer Contracts pursuant to termination rights accruing from the occurrence of a termination of this Agreement or otherwise or (ii) upon timely written request of SIGA, use Commercially Reasonable Efforts to assign any Customer Contract identified in such notice then in force to SIGA.', 'Promoter will maintain a record of each Safety Report received, including relevant source documents, and a record of each Safety Report reported to SIGA for a minimum period of ten (10) years after the expiration or termination of this Agreement and, if requested, will provide these and any other information requested by SIGA.']"
BravatekSolutionsInc_20170418_8-K_EX-10.1_10205739_EX-10.1_Reseller Agreement.pdf,  RESELLER AGREEMENT,"['Bravatek Solutions, Inc.', 'the company set forth below (""Company"") (each, individually, a ""party"" and collectively, ""parties""):', 'i3 ICS', 'Reseller', 'i3 Integrative Creative Solutions, LLC', 'BVTK']","['7th day of April, 2017']",04-07-2017,['Contract is renewable for 1 year extension by amendment to this agreement.'],Virginia,"['During the Term hereof and for a period of six (6) months following the termination of this Agreement or the discontinuation of any of the Company Products, (i) the Reseller shall have the exclusive right to commission for any Registered Referrals, (ii) the Company shall not market, promote, sell, or distribute Company Products or solicit or procure orders for the Company Products, or for any product(s) or service(s) similar to the Company Products, in the Territory other than through the Reseller and pursuant to this Agreement, except with the prior written consent of the Reseller, and (iii) without limitation to the foregoing, the Company shall not, directly or through other parties (whether agents, representatives, intermediaries, resellers or other parties), market, promote, sell, distribute, solicit or procure orders to any existing or prospective customer of the Reseller.']","['During the Term hereof and for a period of six (6) months following the termination of this Agreement or the discontinuation of any of the Company Products, (i) the Reseller shall have the exclusive right to commission for any Registered Referrals, (ii) the Company shall not market, promote, sell, or distribute Company Products or solicit or procure orders for the Company Products, or for any product(s) or service(s) similar to the Company Products, in the Territory other than through the Reseller and pursuant to this Agreement, except with the prior written consent of the Reseller, and (iii) without limitation to the foregoing, the Company shall not, directly or through other parties (whether agents, representatives, intermediaries, resellers or other parties), market, promote, sell, distribute, solicit or procure orders to any existing or prospective customer of the Reseller.']"
HealthcareIntegratedTechnologiesInc_20190812_8-K_EX-10.1_11776966_EX-10.1_Reseller Agreement.pdf,WALABOT-HOME RESELLER AGREEMENT,"['Inde Living Holdings, Inc.', 'Reseller', 'Vayyar Imaging Ltd.', 'Vayyar and Reseller shall be referred to individually as ""Party"" and collectively as ""Parties"".', 'Supplier']",['31 day of July 2019'],7/31/19,"['Thereafter, this Agreement shall automatically be renewed for successive 1-year terms (each a ""Renewal Term"", and together with the Initial Term, the ""Term"").']",New York,[],"[""In addition to the foregoing, if, at the time of termination of this Agreement, Reseller shall have additional Product units in its inventory and is able to sell them to Customers and/or End Users (including, without limitation, any Product units for which Reseller has or is obligated to pay the Supplier the purchase price therefor but which have not yet been delivered to the Reseller by Supplier, which Supplier hereby agrees to either deliver as otherwise contemplated by this Agreement as if it had not terminated or to refund the purchase price therefor), then the licenses and appointments described in Section 2 shall remain in effect with respect to such unsold Product units (and such Section 2 shall not terminate) until the earlier of (i) the date on which the last Product in Reseller's inventory is sold to a Customer and/or End User, or (ii) 1 year from the date of the termination of this Agreement.""]"
EhaveInc_20190515_20-F_EX-4.44_11678816_EX-4.44_License Agreement_ Reseller Agreement.pdf,LICENSE AND RESELLER AGREEMENT,"['EHAVE, INC.', 'COMPANION HEALTHCARE TECHNOLOGIES CORP', 'Ehave', 'CHT']","['October 30, 2018']",10/30/18,[],"Ontario, Canada","['Notwithstanding anything to the contrary contained herein, the exclusive appointment and license set out in Sections 2(a) and 2(b) shall become non-exclusive if: (i) at any time during the Term hereof, CHT breaches Section 2(d) as determined by arbitration in accordance with Section 19(c) or by a final non-appealable judgment of a court of competent jurisdiction; or (ii) at any time after November 1, 2010 CHT fails to achieve annual revenues of $500,000.', 'Subject to Section 2(e), the grant set out in Clause 2(b)(i) is exclusive such that Ehave shall not license any other Person to, nor may Ehave itself, license, sub-license the use of, or provide services similar to, the Ehave Companion Solution within the Field of Use anywhere in the Territory.', 'Subject to Section 2(e), the foregoing appointment is exclusive such that Ehave shall not appoint any other Person to, nor may Ehave itself, sell or resell the use of the Ehave Companion Solution within the Field of Use anywhere in the Territory.']","['Without limiting the provisions of Section 11, commencing on the delivery of any notice of termination of this Agreement, and continuing through the effective date of termination and for a period of sixty (60) Business Days thereafter (the ""Transition-out Period""), Ehave will, to the extent requested by CHT, provide to CHT (or at CHT\'s request to CHT\'s End User) such reasonable cooperation, assistance and services to facilitate the orderly wind down, transition and migration and transfer of the End User Data from Ehave to CHT (the ""Transition-out Services"").', ""Upon the termination of this Agreement for any reason, subject to and without limiting the provisions of Section 12: (i) the Parties shall implement the Transition-Out Services pursuant to Section 10(f); (ii) at the end of the Transition-out Period (or earlier upon CHT's request) Ehave shall terminate and invalidate any Authentication IDs associated with CHT and any of its End Users; (iii) Ehave shall, but not earlier than twenty (20) Business Days after the later of termination or expiration of this Agreement or the Transition-out Period, destroy any copies of the End User Data contained in the Ehave Companion Solution and certify in writing to CHT that it has done so; (iv) CHT shall pay to Ehave the full amount of all Royalties payable hereunder as of the date of termination, if any, whether already invoiced or not (including any amounts due as late payment charges), and any other monies owing to Ehave hereunder; and (v) each Party will return to the other Party, or at the other Party's written request, destroy, in a secure manner all Confidential Information of the other Party which is then in its possession or control and certify in writing that it has done so.""]"
IpassInc_20181203_8-K_EX-99.1_11445874_EX-99.1_Reseller Agreement.pdf,CHANNEL PARTNER RESELLER AGREEMENT,"['iPass', 'Channel Partner', 'IPASS INC.', 'Pareteum Corporation']",['04/25/2018'],4/25/18,"['The Agreement shall automatically renew for successive one (1) year terms (each a ""Renewal Term"") unless either party provides the other party written notification of its intent to terminate the Agreement no later than sixty (60) days prior to the end of the then applicable term.']",California,"['Channel Partner accepts iPass as the exclusive provider to Channel Partner for all services of the nature of the Services. In no event may Channel Partner resell or otherwise provide the Service to any third party for purposes of further ""down channel"" resale of the Services, absent iPass\' notice and consent.']",[]
AlliedEsportsEntertainmentInc_20190815_8-K_EX-10.34_11788308_EX-10.34_Sponsorship Agreement.pdf,EVENT SPONSORSHIP AGREEMENT,"['Newegg Inc.', 'Allied Esports International, Inc.', 'Newegg', 'Allied', 'Newegg and Allied are hereinafter referred to jointly as the ""Parties"" and each as a ""Party.""']","['February 1, 2019']",02-01-2019,[],California,"['Allied shall not endorse, or permit the marketing of any other company whose principal business is as an e-commerce provider at or in connection with the Arena.', ""Without limitation of the preceding sentence or any other provision of this Agreement, Allied shall identify and name Newegg as a Founding Partner, and as the exclusive Technology E-Commerce (or E-tail) Partner, of the Arena and in all of Allied's marketing materials in connection with the Arena where reasonably practicable."", ""In all of Allied's actions and publications (in all media and formats) in connection with the marketing and conducting of the Events, where possible and appropriate, Allied shall where reasonably practicable communicate that Newegg is the exclusive sponsor of the Arena for the technology e-commerce and online retailer categories.""]",[]
EcoScienceSolutionsInc_20180406_8-K_EX-10.1_11135398_EX-10.1_Sponsorship Agreement.pdf,SPONSORSHIP AGREEMENT,"['Eco Science Solutions, Inc.', 'Sponsor', 'Fruit of Life Productions LLC', 'Promoter']","['1st day of April, 2018 (']",04-01-2018,[],Florida,[],[]
AgapeAtpCorp_20191202_10-KA_EX-10.1_11911128_EX-10.1_Supply Agreement.pdf,ODM SUPPLY AGREEMENT,"[""'the Customer'"", 'ORGANIC PREPARATIONS INC.', ""'the Manufacturer'"", 'AGAPE ATP INTERNATIONAL HOLDING LIMITED']",['15t h day of January 2018'],1/15/18,"['This agreement will be automatically renewed at the end of every ten (10) year term, with each subsequent term of renewal being for a ten (10) year term.']",England,"['The Manufacturer hereby appoints the Customer to be the sole and exclusive agent for the promotion, sales, marketing, distribution and administration of the products listed in schedule A of this agreement based on minimum annual product purchase requirements as listed in Schedule B of this agreement.', 'The Manufacturer covenants not to sell any product listed in this agreement, or product name (as listed in schedule A of this agreement) to any other party without prior written consent of the Customer.', 'The Manufacturer grants exclusive rights to the Customer for the term of ten (10) years from the date of the signing of this agreement and for an indefinite period upon the customer fulfilling the minimum annual purchase requirement as listed in Schedule B. of this agreement.', 'The Manufacturer agrees to give the Customer exclusive rights to the marketing, promotion and sales of the new products should the Customer decide to take on the new products.']",[]
FreezeTagInc_20180411_8-K_EX-10.1_11139603_EX-10.1_Sponsorship Agreement.pdf,Corporate Sponsorship Agreement,"['Freeze Tag Inc.', 'Company', 'Association', 'American Diabetes Association, Inc.']","['March 22, 2018']",3/14/18,[],Virginia,[],[]
ReynoldsConsumerProductsInc_20191115_S-1_EX-10.18_11896469_EX-10.18_Supply Agreement.pdf,MASTER SUPPLY AGREEMENT,"['PACTIV LLC', 'Seller and Buyer are referred to individually at times as a ""Party"" and collectively at times as the ""Parties"".', 'Buyer', 'Seller', 'REYNOLDS CONSUMER PRODUCTS LLC']","['November 1, 2019']",11-01-2019,[],Illinois,[],[]
WestPharmaceuticalServicesInc_20200116_8-K_EX-10.1_11947529_EX-10.1_Supply Agreement.pdf,GLOBAL MASTER SUPPLY AGREEMENT,"['Buyer', 'on behalf of itself and the Buyer affiliates listed on Attachment C (each a ""Buyer Affiliate"" or ""West/A"" or collectively, ""Buyer Affiliates"").', 'ExxonMobil Chemical Company', 'Seller', 'on behalf of itself and in the interest of the ExxonMobil affiliates listed on Attachment B (each an ""ExxonMobil Selling Affiliate"" or ""EMCC/A"" or collectively, ""ExxonMobil Selling Affiliates""),', 'West Pharmaceutical Services, Inc.']","['January 10, 2020']",01-01-2019,[],Texas; Singapore; Belgium,[],[]
HertzGroupRealtyTrustInc_20190920_S-11A_EX-10.8_11816941_EX-10.8_Trademark License Agreement.pdf,FORM OF TRADEMARK LICENSE AGREEMENT,"['HERTZ INVESTMENT GROUP, LLC', 'Licensor', '""Licensee"" and together with Licensor, the ""Parties""),', 'HERTZ GROUP REALTY TRUST, INC.']","['September ___, 2019']",09/[]/2019,[],California,[],[]
ArconicRolledProductsCorp_20191217_10-12B_EX-2.7_11923804_EX-2.7_Trademark License Agreement.pdf,FORM OF TRADEMARK LICENSE AGREEMENT,"['Licensor', 'Licensee', 'ARCONIC ROLLED PRODUCTS CORP.', 'ARCONIC INC.']","['[ ] day of [ ], 2020 (']",[]/[]/2020,[],Delaware,[],[]
MorganStanleyDirectLendingFund_20191119_10-12GA_EX-10.5_11898508_EX-10.5_Trademark License Agreement.pdf,TRADEMARK LICENSE AGREEMENT,"['Licensor', 'Licensee', 'Morgan Stanley Direct Lending Fund', 'Morgan Stanley Investment Management Inc.']","['[¬∑] day of [¬∑], 2019']",[]/[]/2019,[],New York,[],[]
NmfSlfIInc_20200115_10-12GA_EX-10.5_11946987_EX-10.5_Trademark License Agreement.pdf,TRADEMARK LICENSE AGREEMENT,"['the ""Licensee""', 'NMF Senior Loan Fund I, Inc.', 'New Mountain Capital, L.L.C.', 'the ""Licensor""', 'The Licensor and the Licensee are sometimes referred to herein separately as a ""party"" and collectively as the ""parties.""']","['[¬∑], 2019']",[]/[]/2019,[],New York,[],"['For twenty-four (24) months following termination of this Agreement, the Licensee shall specify on all public- facing materials in a prominent place and in prominent typeface that the Licensee is no longer operating under the Licensed Mark, is no longer associated with the Licensor, or such other notice as may be deemed necessary by the Licensor in its sole discretion in its prosecution, defense, and/or settlement of any Third Party Claim.']"
PalmerSquareCapitalBdcInc_20200116_10-12GA_EX-10.6_11949289_EX-10.6_Trademark License Agreement.pdf,TRADEMARK LICENSE AGREEMENT,"['Palmer Square Capital Management LLC', 'the ""Licensor""', 'the ""Licensee""', 'Palmer Square Capital BDC Inc.']","['[ ] day of [ ], 2020']",[]/[]/2020,[],New York,[],"['For twenty-four (24) months following termination of this Agreement, Licensee shall specify on all public-facing materials in a prominent place and in prominent typeface that Licensee is no longer operating under the Licensed Mark, is no longer associated with Licensor, or such other notice as may be deemed necessary by Licensor in its sole discretion in its prosecution, defense, and/or settlement of any Third Party Claim.']"
PenntexMidstreamPartnersLp_20150416_S-1A_EX-10.4_9042833_EX-10.4_Transportation Agreement.pdf,GAS TRANSPORTATION AGREEMENT,"['MRD Operating LLC', 'PennTex North Louisiana Operating, LLC', 'Customer', 'Transporter', 'Hereinafter, Transporter and Customer may sometimes be referred to collectively as the ""Parties"" and individually as a ""Party']","['14t h day of April, 2015']",4/14/15,"['This Agreement shall commence on the Effective Date and continue in full force and effect until the end of the fifteenth (15th) Contract Year, and shall continue in full force and effect thereafter until terminated by either Party by providing thirty (30) calendar days\' prior written notice of termination to the other Party (such fifteen (15) Contract Year period, as may be further extended as provided herein is referred to as the ""Term"").']",Texas,"['AMI/MEA Agreement"" shall mean that certain Amended and Restated Area of Mutual Interest and Midstream Exclusivity Agreement dated April 14, 2015 among PennTex North Louisiana, LLC, Customer, PennTex NLA Holdings, LLC and MRD WHR LA Midstream LLC, as such agreement may be amended, supplemented or otherwise modified from time to time.<omitted>During the Term, subject to the terms of the AMI/MEA Agreement, Customer dedicates and commits to this Agreement, and shall deliver or cause to be delivered to the Transportation System for transportation hereunder, all of Customer\'s owned or controlled residue Gas delivered from any of the Plants.']",[]
TcPipelinesLp_20160226_10-K_EX-99.12_9454048_EX-99.12_Transportation Agreement.pdf,TRANSPORTATION SERVICE AGREEMENT Contract Identification FT18150,"['Great Lakes Gas Transmission Limited Partnership', 'ANR PIPELINE COMPANY', 'Shipper', 'Transporter']","['December 14, 2015']",11-01-2016,[],Michigan,[],[]
RangeResourcesLouisianaInc_20150417_8-K_EX-10.5_9045501_EX-10.5_Transportation Agreement.pdf,TRANSPORTATION SERVICES AGREEMENT,"['Shipper and Carrier may be referred to individually as a ""Party,"" or collectively as the ""Parties.""', 'Carrier', 'Shipper', 'MRD Operating LLC', 'PennTex North Louisiana Operating, LLC']","['14t h day of April, 2015']",4/14/15,"['This Agreement shall commence on the Effective Date and continue in full force and effect until the end of the fifteenth (15th) Contract Year, and shall continue in full force and effect thereafter until terminated by either Party by providing thirty (30) calendar days\' prior written notice of termination to the other Party (such fifteen (15) Contract Year period, as may be further extended as provided herein is referred to as the ""Term"").']",Texas,[],[]
ZtoExpressCaymanInc_20160930_F-1_EX-10.10_9752871_EX-10.10_Transportation Agreement.pdf,Road Transportation Agreement,"['Party A (Shipper): ZTO Express Co., Ltd.', 'Party B (Carrier): Tonglu Tongze Logistics Ltd.']","['December 22, 2014']",12/22/14,[],People's Republic of China,[],[]
AudibleInc_20001113_10-Q_EX-10.32_2599586_EX-10.32_Co-Branding Agreement_ Marketing Agreement_ Investment Distribution Agreement.pdf,"CO-BRANDING, MARKETING AND DISTRIBUTION AGREEMENT","['ACSI', 'Audible Inc.', 'Amazon.com Commerce Services, Inc.', 'Company', 'ACSI and Company are sometimes referred to collectively herein as the ""Parties"" and individually as a ""Party.""']","['January 30, 2000']",1/30/00,[],Washington,"[""The Parties will issue a joint press release promptly upon concluding Advertising. this Agreement, which press release shall be subject to the Party's mutual approval, which shall in any event state that Company is the exclusive provider on the ACSI Site of premium spoken-word audio product for download or streaming over the world wide web."", 'During the Term, [***], ACSI will not offer or sell through the ACSI Site, or authorize any third party to sell through the ACSI Site, any Exclusive Spoken-Word Audio Products; [***].']","[""Upon any termination or expiration of the Term the Parties will cooperate in good faith to promote a smooth customer transition, and in any event, Company will, at ACSI's option, continue to operate the Mirror Company Site and offer Spoken-Word Audio Products through the Spoken-Word Audio Sub-Section in accordance with the terms of this Agreement for a period of up to six (6) months following such termination.""]"
2ThemartComInc_19990826_10-12G_EX-10.10_6700288_EX-10.10_Co-Branding Agreement_ Agency Agreement.pdf,CO-BRANDING AND ADVERTISING AGREEMENT,"['2THEMART.COM, INC.', '2TheMart', 'i-Escrow', 'I-ESCROW, INC.']","['June 21, 1999']",6/21/99,"['In the event that either party does not give such notice, the term of this Agreement shall be automatically renewed for another one (1) year.', 'A party wishing to renew this Agreement shall give the other party notice thereof no less than thirty (30) days before the expiration of the term then in effect.']",California,[],"['Notwithstanding the foregoing, unless this Agreement was terminated for a material breach, all provisions of this Agreement shall survive to the extent necessary for i-Escrow to complete any Customer transactions which are pending at the time of expiration or termination.']"
EmbarkComInc_19991008_S-1A_EX-10.10_6487661_EX-10.10_Co-Branding Agreement.pdf,CO-BRANDING AGREEMENT,"['Sponsor', 'Snap Technologies, Inc.', 'United Airlines, Inc.', 'Snap']","['June 8, 1999']",06-08-1999,[],California,"['During the Term, Snap will not grant any third party any right to sponsor any products or services in the Exclusive Category on or through the Snap Web Site.', 'For the avoidance of doubt, the parties acknowledge that the foregoing restriction applies only to persistent sponsorship placement as judged by Sponsor at its discretion, and not to run-of-site banner advertisements or other rotating promotional placements.']",[]
HealthcentralCom_19991108_S-1A_EX-10.27_6623292_EX-10.27_Co-Branding Agreement.pdf,CO-BRANDING CONTENT AGREEMENT,"['HEALTHCENTRAL.COM INC.', 'MEDIALINX INTERACTIVE, L.P.', 'MLX', 'HCI']",['30th day of June 1999'],09-01-1999,[],"Ontario, Canada","['HCI shall not either directly or indirectly license or deliver content to or carry on or be engaged with any other Canadian portal web site, being a Web site which aggregates and markets a variety of content directed to multiple communities of interest and which offers products,\n\nSource: HEALTHCENTRAL COM, S-1/A, 11/8/1999\n\n\n\n\n\ntools and services to a broad base of Canadian end users.', 'During the Term of the Agreement, and subject to the following requirements respecting Canadian content levels as set out in paragraphs 3(f), (g) and (h), HCI shall be the exclusive health content partner in the health section of the Sympatico web site, provided however, that nothing contained herein shall prevent MediaLinx from entering into an agreement with other parties for: i) a health based web directory; or ii) other health related content whose content does not compete with the content contained on the Co-Branded Site; which in no event shall receive no more than one fifth (1/5th) of the promotion and which shall constitute no more than one fifth (1/5th) of the total health related content which resides on the home page of the Sympatico Health section.', 'If, at any time during the Term of this Agreement, HCI fails to meet the content requirements set out in paragraphs 3(f), (g) and (h), HCI shall no longer be entitled to be the exclusive health content partner in the health section of the Sympatico web site.']",[]
ImpresseCorp_20000322_S-1A_EX-10.11_5199234_EX-10.11_Co-Branding Agreement.pdf,CO-BRANDING AGREEMENT,"['Impresse Corporation', 'VerticalNet, Inc.', 'VerticalNet', 'Impresse']","['March 3, 2000']",03-03-2000,[],Delaware,[],"[""During the term of this Agreement and for one year thereafter, VerticalNet shall have the right to appoint a certified public accountant to audit Impresse's financial records relating to such payment to verify the accuracy of Impresse's financial records in order to verify the amount of the payments owed and/or paid hereunder, but no more frequently than once per year.""]"
EbixInc_20010515_10-Q_EX-10.3_4049767_EX-10.3_Co-Branding Agreement.pdf,CO-BRANDING AGREEMENT,"['ebix.com, Inc.', 'ebix', 'About', 'About.com, Inc.']","['19th day of January, 2001']",1/19/01,[],Illinois; New York,"['The Insurance Center shall be hosted solely by ebix and contained in an About Wrapper and ebix shall, during the Term, provide site maintenance services relative to the Insurance Center substantially as provided for the ebix Site from time to time, subject to the uptime requirements as set forth in Section 13.4  [TERMINATION AND SURVIVAL].', 'During the Term, ebix shall be the exclusive integrated online insurance provider in the Channels and Guide Sites listed in Section 3.1  [DEVELOPMENT, OPERATION AND ADMINISTRATIO...] above. [**]']",[]
InvendaCorp_20000828_S-1A_EX-10.2_2588206_EX-10.2_Co-Branding Agreement.pdf,CO-BRANDING AGREEMENT,"['At Home Corporation (""Excite@Home"" or ""Excite"")', 'e-centives, Inc., (""Application Provider"" or ""e-centives"")']","['16th day of February, 2000']",2/16/00,[],California,[],"[""Upon termination of this Agreement for reasons other than a           relationship with an Excite@Home Named Competitor under Section           16.a.v., the parties will communicate with Program Members as follows:\n\n       i)   Excite@Home will email Program Members on e-centives' behalf up                to a maximum of two times. Consistent with other communications                envisioned during the Term of the Agreement, such mailings will                be branded Excite@Home but will alert Program Members that this                Agreement is to be terminated, the Co-Branded Application will<omitted>continue with e-centives branding, and Program Members will                continue as a participant in the e-centives service unless they                explicitly opt out.  The content and copy of such emails shall be                mutually agreed upon.\n\n       ii)  The first email will be exclusive to e-centives (i.e., it will                not mention similar services from Excite@Home or other third                parties) and will alert Program Members of the continuation of                the e-centives service directly from e-centives. Program Members                shall be further alerted that their membership in the e-centives                service shall continue unless they explicitly opt-out.                Excite@Home shall not promote competing services in such contact                or otherwise discourage Program Members from continuing to use                the e-centives service as provided directly by e-centives.\n\n       iii) The second email will not be exclusive to e-centives. It will                include the same e-centives alerts as in the first email, but may                offer a replacement Excite@Home service and a notification that                the Program Member will remain in such an Excite@Home-provided                service unless they specifically opt-out. Excite@Home shall not                discourage Program Members from continuing to use the e-centives                service directly from e-centives, but may offer an additional                choice. It is conceivable that any one end user customer could                use both services.\n\n       iv)  Any such communications will be subject to Excite@Home's                then-current privacy policy."", ""Effects of Termination<omitted>iii) For a period of up to sixty (60) days, Application Provider will           provide consulting services to Excite@Home, as Excite@Home may           reasonably request and for reasonable fees to be paid to Application           Provider, such fees to be agreed upon in writing by the Parties, to           assist Excite@Home in providing a seamless transition to Program           Members. Application Provider will have no obligation to provide such           services to Excite@Home to the extent that Application Provider's           personnel and resources are unavailable in the amounts requested by           Excite@Home or if the Parties are unable in good faith to agree on the           reasonable fees to be paid to Application Provider for such services.           Application Provider will not be required, in the course of providing           such consulting services to Excite@Home, to disclose or transfer to           Excite@Home any proprietary information, software, or Intellectual           Property of Application Provider or any of its merchant partners."", 'To further ensure a seamless transition for Program Members, in the           event of a termination based upon a material breach by e-centives or           an acquisition pursuant to Section 16.a.v. only, Application Provider           shall continue to host and maintain the Co-Branded Application for a           period of one hundred twenty (120) days following either receipt or           issuance of notice of intention to terminate this Agreement. Such           hosting and maintenance of the Co-Branded Application shall be           provided by Application Provider at such reasonable rates as are           mutually agreed upon by the parties.']"
LeadersonlineInc_20000427_S-1A_EX-10.8_4991089_EX-10.8_Co-Branding Agreement.pdf,CO-BRANDING AGREEMENT,"['VerticalNet', 'LeadersOnline', 'VerticalNet, Inc.', '(each a ""Party"" and together the ""Parties"").', 'LeadersOnline, Inc.']","['March 15, 2000']",3/15/00,"['LeadersOnline shall have the option, subject to VerticalNet\'s approval exercised in its sole  and absolute discretion, to extend the Term of this Agreement for an additional 12 months (a ""Renewal Term"") on such terms and conditions as may be mutually agreed upon by the Parties.']",Pennsylvania,[],[]
NeoformaInc_19991202_S-1A_EX-10.26_5224521_EX-10.26_Co-Branding Agreement.pdf,CO-BRANDING AGREEMENT,"['VerticalNet, Inc.', 'VerticalNet', 'Neoforma', 'Neoforma.com, Inc.']","['November 19, 1999']",11/19/99,"['This Agreement will automatically renew at the end of the Initial Term or a subsequent renewal term on a year to year basis (each, a ""Renewal Term""), unless either Party notifies the other at least 30 days prior to the end of the Initial Term or then current Renewal Term, as applicable, of its intention not to renew this Agreement (a ""Termination Notice"").']",Pennsylvania,"['Within 30 days after the Effective Date, Neoforma shall provide a copy of all Neoforma Laboratory Product Listings existing as of the Effective Date to VerticalNet for use on the VerticalNet Sites on an exclusive basis (even as to Neoforma), to the extent Neoforma has the right to do so.', 'Within 30 days after the Effective Date, VerticalNet shall provide a copy of all VerticalNet Medical Product Listings for New Medical Products existing as of the Effective Date to Neoforma for use on Neoforma Plan, Neoforma Shop and Neoforma Auction on an exclusive basis (even as to VerticalNet), to the extent VerticalNet has the right to do so.', 'Neoforma hereby grants VerticalNet an exclusive license to use, modify, enhance, reproduce, display, perform and transmit the Neoforma Career Content, subject to and in accordance with the terms, conditions and provisions of this Agreement.', 'Neoforma hereby grants VerticalNet an exclusive license, even as to Neoforma, to use, modify, enhance, reproduce, display, perform and transmit the Neoforma Laboratory Product Listings, subject to and in accordance with the terms, conditions and provisions of this Agreement, to the extent Neoforma has the right to do so.', 'Neoforma shall not place any Link on a Neoforma Site to, or a Neoforma Link on the Site of, any other provider or host of a service similar to the Co-Branded Training and Education Center or to any other training or education service websites.', 'From time to time during the Term, VerticalNet shall provide a copy of all VerticalNet Medical Product Listings received by VerticalNet after the Effective Date to Neoforma as such Product Listings are made available to VerticalNet for use on Neoforma Plan, Neoforma Shop and Neoforma Auction on an exclusive basis (even as to VerticalNet), to the extent VerticalNet has the right to do so.', 'During the Term, VerticalNet shall have the exclusive right to arrange for the sale of all advertising on the Co-Branded Sites, subject to reasonable approval of each such advertiser by Neoforma.', 'VerticalNet hereby grants Neoforma an exclusive license, even as to<omitted>VerticalNet, to use, modify, enhance, reproduce, display, perform and transmit the VerticalNet Medical Product Listings, subject to and in accordance with the terms, conditions and provisions of this Agreement, to the extent that VerticalNet has the right to do so.', 'Within 30 days after the Effective Date, VerticalNet shall provide a copy of all VerticalNet Medical Product Listings for Used and Excess Medical Products existing as of the Effective Date to Neoforma for use on Neoforma Plan, Neoforma Shop and Neoforma Auction on an exclusive basis (even as to VerticalNet), to the extent VerticalNet has the right to do so.', 'Neoforma hereby grants VerticalNet an exclusive license to use, modify, enhance, reproduce, display, perform and transmit the Neoforma T&E Content, subject to and in accordance with the terms, conditions and provisions of this Agreement.', 'Notwithstanding the foregoing, VerticalNet\'s activities in connection with its ""Storefronts"" and ""E-Commerce Centers"" (as conducted today, in a fashion substantially similar to the manner in which such activities are conducted today or as otherwise mutually agreed upon by the parties, which agreement shall not be unreasonably withheld or delayed) shall not be considered to be a breach of Section 2.1  [MEDICAL PRODUCTS], 2.2  [MEDICAL PRODUCTS] or 2.3  [MEDICAL PRODUCTS].']","['If a Termination Notice is sent, the parties shall promptly meet to discuss a phase-out of the Co-Branded Sites and all Links and transfers of Product Listings set forth herein.']"
PaperexchangeComInc_20000322_S-1A_EX-10.4_5202103_EX-10.4_Co-Branding Agreement.pdf,CO-BRANDING AGREEMENT,"['PaperExchange', 'PaperExchange.com, LLC', 'VerticalNet, Inc.', 'VerticalNet']",[],9/30/99,"['This Agreement will automatically renew at the end of the Initial Term or a subsequent renewal term on a year to year basis (each, a ""Renewal Term""), unless either party notifies the other at least 30 days prior to the end of the Initial Term or then current Renewal Term, as applicable, of its intention not to renew this Agreement.']",Pennsylvania,"['PaperExchange shall retain the right to place advertisements for its own account on the remaining ***** of the Third Party Advertising Allocation; provided, however, that if any portion of such Third Party Advertising Allocation remains unsold 45 days after it becomes available for advertising, VerticalNet shall have the exclusive right to arrange for third party advertising on such unsold Third Party Advertising Allocation.', 'During the Term, VerticalNet shall have the exclusive right to arrange for the sale of ***** of the third party advertising inventory (which shall consist of a minimum of one advertisement per page on each of the ""Co-Branded Equipment,"" ""Co-Branded Careers,"" ""Resources"" and ""Home Page"" sections or successor, replacement or substitute sections) of the PaperExchange Site and shall be consistent with the amount of advertising on other business to business vertical sites on the PaperExchange Site (the ""Third Party Advertising Allocation"").', 'PaperExchange hereby grants VerticalNet an exclusive license to use, modify, enhance, reproduce, display, perform and transmit the PaperExchange Content, subject to and in accordance with the terms, conditions and provisions of this Agreement.']","[""Upon termination of this Agreement,<omitted>(b) VerticalNet shall be responsible for all charges, payments or expenses incurred by it in connection with the removal of the PaperExchange Links from Co-Branded Sites and the modification of the Co-Branded Sites, including, but not limited to, the removal of PaperExchange Content; (c) PaperExchange shall be responsible for all charges, payments or expenses incurred by it in connection with the removal of the VerticalNet Links, VerticalNet Content and VerticalNet Archived Content from the PaperExchange Site;<omitted>(i) VerticalNet shall retain ownership of the URLs at which the Co-Branded Sites are located, (I) the Co-Branded URLs shall be owned by the party that offers to pay the highest amount to the other for the ownership of such URLs upon payment of such amount to the other party (k) if the agreement is terminated during the Initial Term by VerticalNet pursuant to Section 8.2  [Termination for Cause], (x) VerticalNet shall be released from its obligations under Section 5.8.1  [Non-Competition] and (y) PaperExchange's obligations under Sections 7.2  [Advertising Revenue] and 7.4  [Revenue Sharing] shall be extended for one year after the date of such termination, and (I) if the agreement is terminated during the Initial Term by PaperExchange pursuant to Section 8.2  [Termination for Cause], VerticalNet shall pay to PaperExchange, as liquidated damages, an amount equal to the product determined by multiplying (1) a fraction, the numerator of which shall be the number of days between the effective date of termination and the scheduled expiration date of the Initial Term, and the denominator of which shall be the number of days<omitted>between the Effective Date and the scheduled expiration date of the Initial Term, by (2) *****""]"
RaeSystemsInc_20001114_10-Q_EX-10.57_2631790_EX-10.57_Co-Branding Agreement.pdf,CO-BRANDING AGREEMENT                                      (FORM),"['NETTAXI', '""SpinRecords.com""  or  ""Client""', 'Solutions  Media,  Inc.,  dba SpinRecords.com', 'NETTAXI Online Communities, Inc.']","['Nov  5,  1999']",11-05-1999,"['This  Agreement  shall  be effective upon the<omitted>Effective Date and shall remain in force for a period of one (1) year, and shall be automatically renewed for successive periods of one (1) year unless otherwise terminated  as provided  herein.']",California,[],[]
RandWorldwideInc_20010402_8-KA_EX-10.2_2102464_EX-10.2_Co-Branding Agreement.pdf,CO-BRANDING AGREEMENT,"['PlanetCAD Inc. (formerly known as Spatial Technology Inc.)', '(""Dassault Systemes"") and/or certain affiliates of Dassault Systemes,', 'PlanetCAD', 'Dassault Systemes', '(each a ""Party,"" together, the ""Parties"").']","['November 14, 2000']",11/14/00,['The Agreement shall automatically renew for successive one year additional terms unless terminated by either party at least six months prior to the expiration of the then-current term.'],New York,[],[]
TheglobeComInc_19990503_S-1A_EX-10.20_5416126_EX-10.20_Co-Branding Agreement.pdf,CO-BRANDING Agreement,"['The Boxlot Company', 'Boxlot', 'theglobe', 'theglobe.com, Inc.']","['March ___, 1999']",03/[]/1999,[],New York,[],[]
StampscomInc_20001114_10-Q_EX-10.47_2631630_EX-10.47_Co-Branding Agreement.pdf,MANIFEST SYSTEM SERVICES AND CO-BRANDING AGREEMENT,"['MBE', 'iShip.com, Inc.', 'MAILBOXES ETC. USA, INC.', 'Mail                                                         ------- Boxes Etc. USA, Inc.', 'Company']","['April 27, 1999']",4/27/99,"['MBE shall have the right to elect by written notice to the Company at any time between two (2) and six (6) months prior to the end of such initial term or any subsequent Renewal Period (as defined below), to notify the Company that MBE elects to seek to extend such term for additional two (2)-year periods (each a ""Renewal Period"") In the event of such election, MBE and the Company shall have  -------------- a period of sixty (60) days in which to negotiate commercially reasonable Basic Fees, Bounty Fees and eBay Fees (and other applicable fees) (""Fee Schedule"")                                                               ------------ under which the Company would be willing to renew this Agreement for such Renewal Period.', 'If MBE notifies the Company of its intent to so renew prior to the end of such initial term or such Renewal Period, the term of this Agreement shall automatically be extended for the Renewal Period and, other than the Fee Schedule, all of the terms and conditions of this Agreement shall remain in full force and effect.']",California,"['The Company shall not enter into any agreement or arrangement,      including without limitation any sale, license, service agreement,      co-branding agreement, co-marketing agreement or linking agreement with any      provider of manifesting or shipping services through non-carrier retail      shipping locations; provided, however, that:\n\n               (A) the Company may provide listings of carrier drop-boxes or      carrier-owned counter drop-off locations specific to a particular carrier      (including, without limitation, locations within retail establishments) on      the Company Site, provided that such listings do not include retail      shipping locations, including UPS authorized shipping outlets, FedEx      authorized shipping centers and other commercial mail receiving agencies;      and\n\n               (B) the Company may enter into any such agreement or arrangement      so long as MBE is given advance written notice of such agreement or      arrangement and such agreement or arrangement prohibits the use of the      Manifest or any Company Technology to manifest or ship packages for retail      customers and provided further that Company terminates service to any such      entity that uses the Manifest or any Company Technology to serve retail      customers.', 'MBE shall not enter into any agreement or arrangement with any      provider of an online or Internet-based manifest system other than the      Company.']","['If this Agreement is terminated or expires in accordance with this Section 15 (other than termination by the Company in the event of an uncured material breach by MBE), then MBE shall have a period of up to twenty-four (24) months from and after the date of such termination, to make arrangements with respect to the conversion of the Service to a non-Company manifest system (the ""Termination Period"").', ""During the Termination Period, the Company will give reasonable cooperation and support to MBE to assure an orderly and efficient transition and, without limiting the generality of the foregoing, at MBE's expense, the Company shall be obligated to provide MBE with data reasonably necessary for MBE to convert or implement the non-Company systems, procedures and practices."", 'During the Termination Period each party will continue to perform its obligations hereunder, and MBE and MBE Centers will continue to pay any applicable fees and payments hereunder to the Company.', 'During the Termination Period and thereafter, and notwithstanding any other provision of this Agreement, MBE will be free to use its own personnel, and/or engage or contract with any third party to use the Specifications to design, develop and market an Internet-based manifest system similar to the Manifest (including products that contain functionality similar to the Service and which have a ""look and feel"" similar or identical to the Manifest), in each case solely for the benefit of MBE and the MBE Centers and international franchisees or licensees of MBE.']"
DigitalCinemaDestinationsCorp_20111220_S-1_EX-10.10_7346719_EX-10.10_Affiliate Agreement.pdf,NETWORK AFFILIATE AGREEMENT,"['Digital Cinema Destinations Corp.', '""Network Affiliate"" and with  NCM, each a ""Party"" and collectively, the ""Parties""', 'NCM', 'National CineMedia, LLC']","['14th day of March, 2011']",[]/[]/[],[],Delaware,"[""Except as permitted by the  Exclusivity Exceptions, during the Term, Network Affiliate shall neither engage nor permit a third party (excluding third party designees of NCM as  provided hereunder) to provide, or itself provide, to any of Network Affiliate's theatres any of the services specifically set forth in the definition of  Service."", ""Subject only to the Exclusivity Exceptions, NCM shall be Network Affiliate's exclusive representative with respect to the procurement of  Inventory (including without limitation all on-screen advertising) for the Advertising Services."", 'During the Term, except as expressly provided in this Agreement, including Section  3.6 (Policy Trailer; Branded Slots); those provisions of Part A of Exhibit A that permit Network Affiliate to engage in certain Lobby Promotions;  Section 3.11 (Grand Openings, Employee Uniforms), collectively, the ""Exclusivity Exceptions"", Network Affiliate shall subscribe for and NCM shall  be the exclusive provider to the theatres of the services specifically set forth in the definition of the ""Service.""']","['Upon termination or expiration of this Agreement, and upon reasonable prior notice to Network  Affiliate, NCM shall be entitled to enter the Theatres upon reasonable prior written notice, and any other premises of Network Affiliate where any  NCM Property may be located, and recover any and all NCM Property, unless Network Affiliate chooses to purchase such Property based on a  straight line five year depreciated value.']"
LinkPlusCorp_20050802_8-K_EX-10_3240252_EX-10_Affiliate Agreement.pdf,AFFILIATE AGREEMENT,"['LKPL', 'Axiometric', 'Link Plus Corporation', 'Axiometric, LLC']","['JULY 15, 2005']",7/15/05,[],Maryland,"['LKPL shall have the exclusive right to market and                            sell AMR Product Suites to entities whose corporate                            headquarters are physically located outside the                            United States and its territories.', 'Axiometric shall have the exclusive right to market                            and sell AMR Product Suites to entities whose                            corporate headquarters are physically located in the                            United States and U.S. territories with the exception                            of Datamatic as defined in 3.3.1 and 3.3.2 below', 'LKPL shall have the exclusive right to market and                            sell AMR Product Suites to Datamatic LTD, a Plano TX                            corporation (hereafter Datamatic).']",[]
SteelVaultCorp_20081224_10-K_EX-10.16_3074935_EX-10.16_Affiliate Agreement.pdf,MARKETING AFFILIATE AGREEMENT,"['National Credit Report.com, LLC', 'Equidata, Inc.', 'Marketing Affiliate', 'Equidata']",['1s t day of October 2008'],10-01-2008,"['This Agreement shall be for the term of one year; thereafter, the Agreement shall renew automatically under these same  terms and agreements unless superceded by future agreements.']",Virginia,[],[]
TubeMediaCorp_20060310_8-K_EX-10.1_513921_EX-10.1_Affiliate Agreement.pdf,CHARTER AFFILIATE AFFILIATION AGREEMENT,"['Network', 'The TUBE Music Network, Inc.', 'Affiliate', 'Tribune Broadcasting Company']","['6t h day of March, 2006']",03-06-2006,"['If the Term is renewed as described in Section 2(b), Network and Affiliate will negotiate exclusively and in good faith concerning further renewal of this Agreement upon mutually-agreed terms and conditions; provided, that unless Network and Affiliate otherwise agree in writing, the exclusive negotiation period will end six (6) months before the expiration of the Term.', 'If Affiliate fails to notify Network of its desire that this Agreement terminate on its expiration date, at least six (6) months before the expiration date, this Agreement will automatically renew, upon the same terms and conditions, for an additional four (4) -year period (""Renewal Term"").']",New York,"['If the Term is renewed as described in Section 2(b), Network and Affiliate will negotiate exclusively and in good faith concerning further renewal of this Agreement upon mutually-agreed terms and conditions; provided, that unless Network and Affiliate otherwise agree in writing, the exclusive negotiation period will end six (6) months before the expiration of the Term.', 'Network hereby grants to Affiliate the exclusive right via Broadcast Television, and Affiliate hereby accepts such exclusive right and the obligation during the Term to broadcast the Service via Broadcast Television (i) over the transmission facilities of each Station identified on Exhibit A, which is licensed by the FCC to serve the community for each such Station (the ""Licensed Community""), for receipt by TV Households in the DMA in which the Licensed Community is located, as such DMA is identified on Exhibit A, and (ii) over the transmission facilities of any Acquired Station, except to the extent that, as of the date Affiliate notifies Network in writing of its binding agreement to acquire such Acquired Station, (A) another Broadcast Television station in the same DMA as the Acquired Station has exclusive rights to broadcast the Service, or (B) the Acquired Station is obligated to broadcast other material that precludes it from also carrying the Service', 'If condition (A) or (B) applies, the Acquired Station shall have no obligations hereunder, and Network shall have the right to license the transmission of the Service to another Broadcast Television station in such DMA, including on an exclusive basis.']","['In the event that Network terminates this Agreement as to a particular Station or several Stations, or in its entirety pursuant to Sections 10(a) or (c), Affiliate shall, within thirty (30) days of termination, at its option either reimburse Network for the cost of all equipment or return such equipment related to such Station(s) that was paid for by Network pursuant to Section 5(b) herein.']"
GridironBionutrientsInc_20171206_8-K_EX-10.1_10972555_EX-10.1_Endorsement Agreement.pdf,ENDORSEMENT AGREEMENT,"['NFLA-NC', 'National Football League Alumni, Inc.', 'Gridiron BioNutrients‚Ñ¢', 'NFLA', 'National Football League Alumni - Northern California Chapter', 'Food For Athletes, Inc', '(collectively the ""Company"").']","['October 30, 2017']",11-01-2017,[],California,['NFLA agrees not to grant the right to use the NFLAs Identification to anyone other than Company in connection with the advertisement and promotion of Products.'],"[""Company may liquidate and sell its inventory of Licensed Products (including any inventory then in production) for a period of ninety (90) days after the termination date of the Contract Period, subject to the Company's continued obligation to pay the Fee as provided above, and will deliver the Sales Report with respect to such liquidation sales within 30 days following the end of the first reached full quarter following termination.""]"
LegacyEducationAllianceInc_20141110_8-K_EX-10.9_8828866_EX-10.9_Endorsement Agreement.pdf,TALENT ENDORSEMENT AGREEMENT,"['Celebrity Speakers', 'Tigrent Learning UK Limited', 'CSA', 'Talent', 'Robbie Fowler', 'Company']",['____ day of ______________ 2013'],01-01-2013,['The period of license granted shall be for the Term and shall extend for a period of twenty four (24) months or until terminated as per clause 8 herein.'],"England, United Kingdom; Wales, United Kingdom",[],"['Talent agrees that Company shall, for a period of nine (9) months (Sell-Off Period) following the effective date of termination, have the right to continue to sell Product bearing  the Property and/or utilize advertising materials and collateral bearing the Property.']"
LifewayFoodsInc_20160316_10-K_EX-10.24_9489766_EX-10.24_Endorsement Agreement.pdf,ENDORSEMENT AGREEMENT,"['Ludmila Smolyansky', 'Lifeway', 'Individual', 'Lifeway Foods, Inc.']","['14th day of March, 2016']",3/14/16,[],Illinois,[],[]
PerformanceSportsBrandsInc_20110909_S-1_EX-10.10_7220214_EX-10.10_Endorsement Agreement.pdf,ENDORSEMENT AGREEMENT,"['Andy North', 'Company', 'Golfers Incorporated', 'North']",['21s t day of February 2011'],2/21/11,[],Florida,"['During the Term of this Agreement and within the  Contract Territory, North agrees not to enter into an agreement with another company or entity for the purpose of endorsing or promoting  products similar to the Endorsed Products.']",['Said books and records shall be maintained for a two (2) year period following the expiration or termination of  this Agreement.']
PharmagenInc_20120803_8-KA_EX-10.1_7693204_EX-10.1_Endorsement Agreement.pdf,ENDORSEMENT AGREEMENT,"['""Celebrity', 'Healthcare Distribution Specialists LLC', 'HDS', 'Paul Silas']","['February 20, 2012']",2/20/12,[],Georgia,"['Celebrity represents and warrants that during the Term and in the Territory, Celebrity will not endorse or  make any appearances or advertisements on behalf of any other multivitamin.']",[]
PrudentialBancorpInc_20170606_8-K_EX-10.4_10474434_EX-10.4_Endorsement Agreement.pdf,Split-Dollar Endorsement Agreement,"['""Employer"")', 'Prudential Bank', 'Employee', 'Jeffrey Hanuscin']","['1st day of June, 2017']",06-01-2017,[],Pennsylvania,[],[]
ArcaUsTreasuryFund_20200207_N-2_EX-99.K5_11971930_EX-99.K5_Development Agreement.pdf,BLOCKCHAIN ADMINISTRATION AND DEVELOPMENT AGREEMENT,"['Fund', 'Blockchain Administrator', 'ARCA CAPITAL MANAGEMENT, LLC', 'ARCA U.S. TREASURY FUND,']","['[___], 2020']",[]/[]/2020,"['This Agreement shall continue in effect for two years from the date hereof, and thereafter shall continue automatically for successive annual periods, provided that such continuance is specifically approved at least annually by (A) the vote of the Board, or by the vote of a majority of the outstanding voting securities of the Fund and (B) the vote of a majority of the Fund\'s directors who are not parties to this Agreement or ""interested persons"" (as such term is defined in Section 2(a)(19) of the Investment Fund Act) of any such party, in accordance with the requirements of the Investment Fund Act.']",New York,[],[]
AimmuneTherapeuticsInc_20200205_8-K_EX-10.3_11967170_EX-10.3_Development Agreement.pdf,"LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT","['Xencor and Aimmune are sometimes referred to herein individually as a ""Party"" and collectively as the ""Parties"".', 'Xencor', 'Aimmune', 'Aimmune Therapeutics, Inc.', 'Xencor, Inc.']","['FEBRUARY 4, 2020']",02-04-2020,[],California,"[""Subject to the terms and conditions of this Agreement, Xencor hereby grants to Aimmune during the Term an exclusive, worldwide, payment-bearing license under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents, and a non-exclusive, payment bearing license under and with respect to Xencor Know-How, in each case, with the right to sublicense solely in accordance with Section 2.3.2, solely to Develop, Manufacture and Commercialize the Product in and for the Licensed Field; provided that notwithstanding the foregoing, Xencor shall retain the right under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents to the extent necessary to perform its obligations under this Agreement."", 'Aimmune hereby grants to Xencor an exclusive license under and with respect to Aimmune Patents, and a non-exclusive license under and with respect to Aimmune Know-How, in each case, where such license is an irrevocable, perpetual, royalty-bearing license, with the right to sublicense, to Develop, Manufacture and Commercialize the Product(s), as the Product(s) exist as of the effective date of such termination, or optimized']","['Upon expiration of this Agreement with respect to a Product in a country, the licenses granted to Aimmune pursuant to this Agreement shall continue in full force and effect on a fully-paid basis.', 'Upon the termination of this Agreement:\n\n14.1.1 all rights and licenses granted to Aimmune hereunder shall immediately terminate and be of no further force and effect and Aimmune shall cease Developing, Commercializing, Manufacturing and Packaging and Labeling such Product in and for all applicable countries; provided, that Aimmune and its Affiliates will be entitled, during the period<omitted>ending on the last day of the [***] following the effective date of such termination, to sell any inventory of Product affected by such termination that remains on hand as of the effective date of the termination, so long as Aimmune pays to Xencor all amounts payable hereunder (including milestones) applicable to said subsequent sales, as applicable, in accordance with the terms and conditions set forth in this Agreement and otherwise complies with the terms set forth in this Agreement.']"
CnsPharmaceuticalsInc_20200326_8-K_EX-10.1_12079626_EX-10.1_Development Agreement.pdf,Development Agreement,"['CNS and WPD are sometimes referred to herein individually as a ""Party"" and collectively as the ""Parties.""', 'WPD', 'CNS Pharmaceuticals, Inc.', 'CNS', 'WPD Pharmaceuticals']","['March 20, 2020']",3/20/20,[],Texas,[],[]
ClickstreamCorp_20200330_1-A_EX1A-6 MAT CTRCT_12089935_EX1A-6 MAT CTRCT_Development Agreement.pdf,APPLICATION DEVELOPMENT AGREEMENT,"['InfinixSoft Global LLC', 'Developer', 'Clickstream Corporation', 'Client']","['March 20, 2020']",3/20/20,[],Florida,"['If the Client, in its reasonable discretion, consents, the Client is hereby granted an exclusive, worldwide, royalty-free, perpetual, irrevocable license to use, distribute, modify, publish, and otherwise exploit the incorporated items in connection with the work product developed for the Client.']",[]
CoherusBiosciencesInc_20200227_10-K_EX-10.29_12021376_EX-10.29_Development Agreement.pdf,LICENSE AND DEVELOPMENT AGREEMENT,"['Licensee', 'Coherus BioSciences, Inc.', 'Bioeq', 'Bioeq IP AG']","['Nov. 02, 2019']",11-02-2019,"[""Except as otherwise specified in this Agreement, the Parties' respective rights and obligations under this Agreement shall commence on the Effective Date and shall remain in full force for ten (10) years after the First Commercial Sale of the first Licensed Product, and shall thereafter automatically renew for an unlimited period of time unless otherwise terminated in accordance with Section 15.2.""]",[],"['For clarity, the exclusive license granted to Licensee pursuant to Section 2.1 shall extend to all Intellectual Property Rights and Know-How Controlled by Bioeq and embodied within, or claiming or covering the Bioeq Improvements.', ""Solely in the event that this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9 or by Licensee pursuant to Section 15.2.5 , Licensee shall grant, and hereby grants to Bioeq an exclusive, royalty-free, fully paid, sublicenseable, license to use the Licensee-Controlled Trademarks which were actually used by Licensee to Commercialize the Licensed Products in the Territory in connection with Bioeq's Commercialization of the Licensed Products in the Territory."", 'Subject to the provisions of this Agreement, Bioeq hereby grants to Licensee an exclusive (even as to Bioeq), milestone- and royalty-bearing, non-transferable license (including the right to grant sublicenses only to the extent permitted by Section 2.1.2) under the Licensed Technology (including the Licensed Patents) to use, sell, have sold, import, have imported or otherwise Commercialize the Licensed Products in the Field in the Territory.']","[""Licensee shall, within [***] ([***]) days of the effective date of termination of the Agreement at the latest (and at no cost to Bioeq if this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5, or at Bioeq's cost and expense if this Agreement is terminated by Licensee pursuant to Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8, as applicable) transfer and assign to Bioeq or its designee all of Licensee's right, title and interest in and to any and all Biologics License Applications and Biologics License Application Approvals controlled by Licensee for the Licensed Products in the Field in the Territory as of the effective date of such termination, including any and all documentation pertaining to such filings and Biologics License Application Approvals (provided that the physical or electronic transfer of files and documentation in connection with such transfer and assignment of rights may occur after such [***] ([***]) day period without being deemed a breach of this Section 15.3.2 by Licensee)"", ""Licensee shall be permitted, at Bioeq's choice (if this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5) or at Licensee's choice (if this Agreement is terminated by Licensee pursuant to Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8), to cither (a) continue selling its and its Affiliates' inventory of Licensed Products existing on the termination effective date in accordance with this Agreement for a maximum period of [***] ([***]) days (in which case all terms and conditions of this Agreement, including Licensee's obligation to report and pay royalties, shall continue to apply to such continued sale) or (b) sell such inventory to Bioeq at the supply price paid by Licensee to Bioeq for such inventory in accordance with the Manufacturing and Supply Agreement."", ""Licensee shall (at no cost to Bioeq if this Agreement is terminated by Bioeq pursuant to Sections 15.2.1, 15.2.2, 15.2.3, 15.2.4, 15.2.8 or 15.2.9, or by Licensee pursuant to Section 15.2.5, or at Bioeq's cost and expense if this Agreement is terminated by Licensee pursuant to Sections 15.2.1, 15.2.6, 15.2.7 or 15.2.8, as applicable) use Commercially Reasonable Efforts to cooperate with Bioeq or its designee, and provide [***] reasonable assistance and support, to [***] Bioeq or its designee to take over the Commercialization of the Licensed Products in the Field in the Territory [***] following the effective date of such termination, including by (a) using Commercially Reasonable Efforts to provide [***], (b) disclosing and assigning (to the extent permitted under the relevant agreement) to Bioeq Licensee's existing agreements relating solely to the Commercialization of the Licensed Product in the Territory, including with [***], to the extent legally possible ([***]) and (c) transferring Licensed Product- specific marketing materials, including [***].""]"
EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement.pdf,Consulting and Product Development Agreement,"['Emerald Health Nutraceuticals Inc.', 'EHS', 'EHN', 'Michael T. Murray, N.D', 'Dr. Murray', 'Emerald Health Sciences Inc.']",['1st day of September 2016'],09-01-2016,"[""The Services Term of this Agreement shall be automatically renewed for successive two-year terms thereafter unless written notice is given by either party to the other, indicating that party's intention not to renew the Services Term of this Agreement, at least ninety (90) days prior to the end of the initial Services Term or any renewed Services Term.""]",Arizona,"[""EHS and EHN shall have the exclusive rights in and to all ingredients, product specifications, goodwill, and all other intellectual property rights associated with any Product(s); provided, however, that EHS and EHN shall not have any rights in or to Dr. Murray's name or likeness except as expressly granted in writing herein or via electronic transmission by Dr. Murray.""]",[]
HarpoonTherapeuticsInc_20200312_10-K_EX-10.18_12051356_EX-10.18_Development Agreement.PDF,DEVELOPMENT AND OPTION AGREEMENT,"['Harpoon Therapeutics, Inc.', 'AbbVie Biotechnology Ltd', 'AbbVie', 'Harpoon']","['November 20, 2019']",11/20/19,[],Delaware,"[""Upon the License Option Exercise Closing Date, Harpoon (on behalf of itself and its Affiliates) hereby grants to AbbVie:\n\n(a) an exclusive (including with regard to Harpoon and its Affiliates, except as provided in Section 5.6) license (or sublicense), with the right to grant sublicenses in accordance with Section 5.3, under the Harpoon Patents, the Harpoon Know-How, and Harpoon's interests in the Joint Patents and the Joint Know-How, to Exploit the Licensed Compounds and Licensed Products in the Field in the Territory;\n\n(b) an exclusive (including with regard to Harpoon and its Affiliates, except as provided in Section 5.6) license and right of reference, with the right to grant sublicenses and further rights of reference in accordance with Section 5.3, under the Regulatory Approvals and any other Regulatory Documentation that Harpoon or its Affiliates may Control with respect to the Licensed Compounds or Licensed Products solely for purposes of Exploiting the Licensed Compounds and Licensed Products in the Field in the Territory."", ""Upon the [***], Harpoon (on behalf of itself and its Affiliates) hereby grants to AbbVie a co-exclusive (with Harpoon), royalty-free (subject to [***] [***]) license, with the right to grant sublicenses in accordance with Section 5.3, under the Harpoon Patents, the Harpoon Know-How, and Harpoon's interests in the Joint Patents and the Joint Know- How, to Develop and Manufacture the Licensed Compounds and Licensed Products solely to the extent necessary for AbbVie to perform [***]."", 'Upon the Effective Date, Harpoon hereby grants to AbbVie the exclusive right, but not the obligation, to obtain the licenses set forth in Section 5.1.3 (the ""License Option"").', ""Effective upon the date that AbbVie commences performing Initial Development Activities pursuant to Section 3.1.2, Harpoon (on behalf of itself and its Affiliates) shall grant and hereby grants AbbVie a co- exclusive (with Harpoon), royalty-free license, with the right to grant sublicenses in accordance with Section 5.3, under the Harpoon Patents, the Harpoon Know-How, and Harpoon's interests in the Joint Patents and the Joint Know-How, solely to the extent necessary for AbbVie to conduct Initial Development Activities assumed by AbbVie in accordance with Section 3.1.2 (if any).""]","[""If AbbVie terminates this Agreement with respect to a country or other jurisdiction, or in its entirety pursuant to Section 12.3, AbbVie shall have the right for at least [***] and no more than [***], which period shall be determined by Harpoon in its sole discretion, after the effective date of such termination with respect to such country or other jurisdiction to sell or otherwise dispose of all Licensed Compound or Licensed Product then in its inventory and any in-progress inventory, in each case that is intended for sale or disposition in such country or other jurisdiction, as though this Agreement had not terminated with respect to such country or other jurisdiction, and such sale or disposition shall not constitute infringement of Harpoon's or its Affiliates' Patent or other intellectual property or other proprietary rights."", 'The insurance policies shall be under an occurrence form, but if only a claims-made form is available to a Party, then such Party shall continue to maintain such insurance after the expiration or termination of this Agreement for the longer of (a) a period of [***] following termination or expiration of this Agreement in its entirety, or (b) with respect to a particular Party, [***] by a Party.']"
IbioInc_20200313_8-K_EX-10.1_12052678_EX-10.1_Development Agreement.pdf,MASTER JOINT DEVELOPMENT AGREEMENT,"['CC-Pharming', 'iBio Inc.', 'Beijing CC-Pharming Ltd.']","['August 08, 2018']",08-08-2018,[],Texas,[],[]
HfEnterprisesInc_20191223_S-1_EX-10.22_11931299_EX-10.22_Development Agreement.pdf,OUTSOURCE TECHNOLOGY DEVELOPMENT AGREEMENT,"['Developer', 'DSS', 'HotApp International Ltd.', 'Document Security Systems, Inc.']","['1s t day of March, 2018']",03-01-2018,"['The Initial Term shall automatically renew for one-month periods thereafter unless either party provides 30- days advance notice of termination, unless earlier terminated pursuant to Section 2.2 hereof']",New York,[],[]
LegacyEducationAllianceInc_20200330_10-K_EX-10.18_12090678_EX-10.18_Development Agreement.pdf,REAL ESTATE EDUCATION TRAINING PROGRAM DEVELOPMENT AGREEMENT,"['T&B Seminars, Inc.', 'LEA', 'Legacy Education Alliance Holdings, Inc.', 'T&B']",['12-23-2019'],12/23/19,['The Term shall automatically renew thereafter for successive 5-year terms unless either party provides prior written notice of termination not less than 90 days prior to the end of such five-year term.'],New York,"['T&B shall not, during the Term, grant any third party a license to use the Licensed Intellectual Property within the Exclusive Field of Use.', 'T&B hereby grants to LEA, and LEA hereby accepts from T&B, during the Term, the sole and exclusive worldwide right and license in and to the Licensed Intellectual Property, which right and license shall be limited to that which is necessary for LEA to (i) develop and create Educational Materials and (ii) develop, promote and conduct the Business worldwide , unless the license is earlier terminated as provided herein.', 'In consideration of the exclusivity rights granted to LEA, commencing with the seventh (7t h) month of the Term and continuing each year of the Term thereafter, the minimum Royalties payable to T&B each month shall be the greater of the (i) applicable monthly Base Royalty and Marketing Royalty or (ii) $200,000.']","['LEA shall, for a period of six (6) months (""Sell-Off Period"") following the effective date of termination of the license granted by T&B hereunder, have the right to fulfill commitments made to customers during the Term']"
LiquidmetalTechnologiesInc_20200205_8-K_EX-10.1_11968198_EX-10.1_Development Agreement.pdf,BUSINESS DEVELOPMENT AGREEMENT,"['LIQUIDMETAL TECHNOLOGIES, INC.', 'Eutectix', 'EUTECTIX, LLC', 'Liquidmetal']","[', 2020']",[]/[]/2020,"['Upon the expiration of the Term, the Term shall automatically extend for successive 12-month periods until one Party terminates the Agreement by providing at least 180 days prior written notice to the other Party prior to the expiration of the then-current term or unless sooner terminated in accordance with the terms of this Agreement.']",Arizona,[],"['To the extent any insurance coverage required under this Agreement is purchased on a ""claims-made"" basis, such insurance shall cover all prior acts of Eutectix during the term of this Agreement, and such insurance shall be continuously maintained until at least two (2) years beyond the expiration or termination of the term of this Agreement, or Eutectix shall purchase ""tail"" coverage, effective upon termination of any such policy or upon termination or expiration of the term of this Agreement, to provide coverage for at least two (2) years from the occurrence of either such event.', 'Upon expiration or termination of this Agreement for any reason, Eutectix shall have the option to purchase some or all of the Licensed Equipment at fair market value, less any amounts owed to Eutectix by Liquidmetal, except the equipment listed under Section 2.1(b) above', ""Upon reasonable prior notice to Eutectix and at Liquidmetal's expense, no more than once per year, during the Term of this Agreement and for one (1) year following the expiration or termination of this Agreement, Liquidmetal or its designee shall have the right from time to time to confirm and validate: (a) that Eutectix has complied with the pricing provisions of this Agreement; (b) Eutectix's financial condition, successorship planning, and ability to continue operations; (c) that Eutectix's performance is consistent with the Agreement; (d) that Eutectix has complied with Article 10 (Compliance) of this Agreement."", 'Notwithstanding the foregoing, with regard to orders received and accepted by Eutectix before expiration or notice of termination, Eutectix may finish making any products in process, may conclude any orders in process, including finishing manufacturing of such products and shipping such products to the customer for up to 6 months after termination or expiration of this Agreement;', 'In the event this Agreement expires or is terminated for any reason other than a breach by Eutectix, Liquidmetal shall purchase from Eutectix existing raw material inventory at the purchase price (including delivery charges) paid by Eutectix to its suppliers in connection with the Orders accepted by Eutectix hereunder.']"
PhasebioPharmaceuticalsInc_20200330_10-K_EX-10.21_12086810_EX-10.21_Development Agreement.pdf,CO-DEVELOPMENT AGREEMENT,"['SFJ', 'each, a ""Party"" and collectively, the ""Parties"").', 'PhaseBio Pharmaceuticals Inc.', 'PB', 'SFJ Pharmaceuticals X, Ltd.']","['January 9, 2020']",01-09-2020,[],Delaware,"['SFJ shall use commercially reasonable efforts to obtain from each Third Party contractor that SFJ or its Affiliate proposes to engage to conduct activities under or in connection with this Agreement on behalf of SFJ or its Affiliates (i) an assignment, (ii) an exclusive, worldwide, royalty-free, fully-paid, freely-assignable license, with the right to sublicense through multiple tiers, or (iii) a non‚Äëexclusive, worldwide, royalty-free, fully-paid, freely-assignable license, with the right to sublicense through multiple tiers ((i) through (iii) in order of preference), to PB of any Trial Invention that such Third Party contractor conceives, discovers, develops or otherwise makes in connection with activities conducted relating to this Agreement.']","['In the event that SFJ terminates this Agreement pursuant to this Section 14.2.3, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to pay SFJ an amount equal to fifty percent (50%) of the Approval Payments (as adjusted as set forth in Section 6.2, subject, to the extent applicable, to Sections 2.3.3 and 3.12.2) that become due and payable under ARTICLE 6 at such time as they become due and payable (if ever) pursuant to ARTICLE 6 (or, as applicable, 50% of any Buy-Out Payment that PB elects to pay pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall also be adjusted as set forth in Section 6.2.', 'within [***] after assignment of the Product Filings pursuant to Section 14.3.2, SFJ shall deliver to PB: (a) true, correct and complete copies of all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates),<omitted>and disclose to PB in writing all previously-undisclosed Research Results within the Trial Data Package; (b) formally transfer or assign, or cause to be formally transferred or assigned, into the name of PB or its designee all Product Filings in such country (in each case, whether held in the name of SFJ or any of its Affiliates); and (c) take such other actions and execute such other instruments, assignments and documents as may be necessary to effect, evidence, register and record the transfer, assignment or other conveyance of such rights to PB or its designee;', 'Additionally, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB will remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that each Approval Payment (or the Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.2.', 'In the event that SFJ terminates this Agreement pursuant to this Section 14.2.6, then, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay to SFJ within [***] of the date of termination an amount equal to one hundred fifty percent (150%) of Development Costs which were paid or incurred by SFJ. PB or its successor (whose performance shall be guaranteed by PB) shall be obligated to continue to exercise Commercially Reasonable Effort to develop the Product and seek Regulatory Approval as set forth herein following the date of such termination including the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such Approval Payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and shall be reduced by the amount previously paid to SFJ as set forth in this Section 14.2.6.', 'In the event of any termination of this Agreement pursuant to Section 14.2, then, if SFJ has not caused a Program Transfer to occur pursuant to Section 3.20:', 'In the event that this Agreement is terminated pursuant to this Section 14.2.4, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to make any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time that such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2.', 'Additionally, PB will remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.5.2.', 'In the event that SFJ terminates this Agreement pursuant to this Section 14.2.8.1, then (a) in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay SFJ, within [***] of the date of termination, an amount equal to one hundred fifty percent (150%) of Development Costs paid or incurred to PB by SFJ prior to such termination, and (b) if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB shall remain obligated to pay to SFJ any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time that such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.8.1.', 'Additionally, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB will remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such payments become due and payable (if ever) (except to the extent PB pays any Buy-Out Payment(s) pursuant to Section 6.7), provided that each Approval Payment (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.1.', 'In the event SFJ terminates this Agreement pursuant to this Section 14.2.5, then in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay SFJ within [***] of the date of termination an amount equal to three hundred percent (300%) of Development Costs paid or incurred by SFJ prior to such termination.', 'In the event that PB terminates this Agreement pursuant to this Section 14.2.2 then in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay SFJ, within [***] of the date of termination, an amount equal to three hundred percent (300%) of Development Costs paid or incurred by SFJ prior to such termination.', ""Notwithstanding the foregoing, if PB terminates this Agreement pursuant to this Section 14.2.1 above based on SFJ's failure to make any payment due to PB in accordance with ARTICLE 4, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB shall remain obligated to pay to SFJ fifty percent (50%) of any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time that such payments become due and payable (if ever) pursuant to ARTICLE 6 (or, as applicable, fifty percent (50%) of any Buy-Out Payment that PB elects to pay pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall also be adjusted as set forth in Section 6.2."", 'Notwithstanding the foregoing, (A) if this Agreement terminates pursuant to this Section 14.2.7 and such termination: (i) arises as a result of gross negligence on the part of PB; or (ii) is due to (x) the applicable independent data monitoring committee recommending termination of the Phase 3 Trial or (y) PB and SFJ<omitted>mutually agreeing to terminate the Phase 3 Trial, in either case ((x) or (y)), due to a Serious Safety Issue that was previously known, demonstrated or identified by PB as being material as of the Effective Date and the material data showing, demonstrating, or identifying such Serious Safety Issue were not included in the Data Room, disclosed in writing to SFJ or otherwise publicly known prior to the Effective Date; then, in either case ((i) or (ii)), PB will pay SFJ within [***] of the date of termination an amount equal to three hundred percent (300%) of Development Costs paid or incurred by SFJ, and (B) if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such Approval Payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2 and shall be reduced by the amount previously paid by PB to SFJ pursuant to this Section 14.2.7.', 'In the event that SFJ terminates this Agreement pursuant to this Section 14.2.9, then in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall pay to SFJ, within [***] of the date of termination, an amount equal to all Development Costs paid or incurred by SFJ as of the date of termination.', 'In the event that SFJ terminates this Agreement pursuant to this Section 14.2.10, then in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB will pay to SFJ, within [***] of the date of termination, an amount equal to the Development Costs paid or incurred by SFJ plus interest at the annual rate of twenty-five percent (25%) from the date such Development Costs were paid or incurred by SFJ and, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, PB shall remain obligated to pay any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such Approval Payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2, and reduced by the amount previously paid to SFJ as set forth in this Section 14.2.10.', 'SFJ shall, and shall cause its Affiliates to, promptly assign to PB or its designee any and all Clinical Trial Agreements, CRO Agreements and other Vendor Agreements to which any of them is a party and cooperate in good faith with PB to provide appropriate notice and new contact information to the applicable Sites, Clinical Investigators, CROs and other Vendors and PB shall accept such assignment of all obligations of SFJ and its Affiliates thereunder without recourse to SFJ other than any indemnification obligations which SFJ may be liable for thereunder.', ""at PB's written request and election in PB's sole discretion, SFJ shall and hereby does, and shall cause its Affiliates to either: (i) wind down in accordance with Applicable Law and observing applicable ethical and regulatory guidelines any or all Clinical Trials being conducted by or on behalf of SFJ or its Affiliate as of the effective date of termination, at SFJ's cost and expense; or (ii) (x) transfer control to PB of any or all Clinical Trials being conducted by or on behalf of SFJ or its Affiliate as of the effective date of termination and (y) continue to conduct such Clinical Trials being conducted by or on behalf of SFJ or an Affiliate as of the effective date of termination for up to [***] to enable such transfer to be completed without interruption of any such Clinical Trial, in each case ((x) and (y)), at PB's cost and expense;"", ""effective as of such termination, SFJ shall, and it hereby does, assign to PB all of SFJ's and its Affiliates' right, title and interest in and to all Product Filings then owned or Controlled by SFJ or any of its Affiliates; provided that if any such Product Filing is not immediately transferable in a country, SFJ shall provide PB with all benefit of such Product Filing and such assistance and cooperation as necessary or reasonably requested by PB to timely transfer such Product Filing to PB or its designee or, at PB's option, to enable PB to obtain a substitute for such Product Filing without disruption to PB's development or Commercialization of the Product in the SFJ Territory;"", 'In the event that PB terminates this Agreement pursuant to this Section 14.2.8.2, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to pay to SFJ any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time that such payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be (A) adjusted as set forth in Section 6.2, and (B) reduced by the amount of all documented out-of-pocket expenses incurred by or on behalf of PB as a result or arising out of such violation by SFJ or any of its Representatives (including any and all amounts paid by PB as penalties or fines for such violation, in settlement of legal or administrative proceedings relating to such violation, or otherwise).', 'In the event that PB terminates this Agreement pursuant to this Section 14.2.5, then, if PB elects to continue development of the Product and obtains Regulatory Approval following such termination, in exchange for purchasing the Trial Data Package including the Research Results included therein as set forth in Section 11.1.1.4, PB shall remain obligated to pay to SFJ any Approval Payments that become due and payable pursuant to ARTICLE 6 at such time as such Approval Payments become due and payable (if ever) pursuant to ARTICLE 6 (except to the extent of the amount of any Buy-Out Payment paid by PB pursuant<omitted>to Section 6.7), provided that such Approval Payments (or Buy-Out Payment, as applicable) shall be adjusted as set forth in Section 6.2.']"
RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement.pdf,"COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT","['Revolution Medicines, Inc.', 'Sanofi and RevMed are referred to in this Agreement individually as a ""Party"" and collectively as the ""Parties.""', 'RevMed', 'Aventis, Inc.', 'Sanofi']","['June 8, 2018']",06-08-2018,[],New York,"['If Sanofi provides a Notice of Interest to RevMed within [***], then (i) RevMed shall, upon request of Sanofi, provide Sanofi with reasonable access to all other then-existing Know-How in RevMed\'s Control that exists in either paper or electronic form and pertains to the relevant SHP1-SHP2 Dual Inhibitor and (ii) the Parties shall negotiate exclusively in good faith and on a commercially reasonable basis the terms of a definitive agreement under which Sanofi would be granted SHP1-SHP2 Dual Inhibitor License Rights for [***] after RevMed receives such Notice of Interest (such period, the ""SHP1-SHP2 Dual Inhibitor Licensing Negotiation Period', 'Subject to the terms and conditions of this Agreement, RevMed hereby grants to Sanofi an exclusive (even as to RevMed and its Affiliates), royalty-bearing license (which shall be sub-licensable solely as provided in Section 3.4) under the RevMed Licensed Technology, to Research, Develop, Manufacture, use, sell, offer for sale, import and otherwise Commercialize and exploit Products (including, for clarity, any Companion Diagnostics with respect to such Products) in the Field in the Licensed Territory.', 'Subject to the terms and conditions of this Agreement, RevMed hereby grants to Sanofi an exclusive option, under the Patent Rights and Know-How claiming or embodied in the [***].']","['RevMed shall pay Sanofi such royalties until the earlier of (x) expiration of the Post-Termination Royalty Term therefor and (y) a Change of Control of Sanofi.', 'Upon any termination of this Agreement, RevMed shall pay to Sanofi any amounts owed to Third Parties under license agreements to which Sanofi is a party that grant Sanofi a license under such Third Party\'s Patent Rights or Know-How that is sublicensed to RevMed pursuant to Section 12.3(c)(ii)A, unless RevMed declines in writing to obtain such sublicense. ""Post-Termination Royalty Term"" means: (I) with respect to a particular country and a particular Termination Product that is the subject of the royalty obligations under Section 12.3(c)(ii)B(1), the period of time commencing upon the First Commercial Sale of such Termination Product in such country (by RevMed or its Affiliates or sublicensees) and ending upon the latest of (a) the date on which there is no Valid Claim (as such term is applied mutatis mutandis to Sanofi Sole Program Patents) of a Sanofi Sole Program Patent that would be infringed by the sale of such Termination Product in such country; (b) the expiration of any Regulatory Exclusivity granted with respect to such Termination Product in such country[***] and (II) with respect to a particular country and a particular Termination Product that is subject of the royalty obligations under Section 12.3(c)(ii)B(2) or Section 12.3(c)(ii)B(3), the period of time commencing upon the First Commercial Sale of such Termination Product in such country (by RevMed or its Affiliates or sublicensees) and ending upon the latest of (a) the expiration of any Regulatory Exclusivity granted with respect to such Termination Product in such country; and (b) [***].', 'Within [***] of the effective date of such termination (or as promptly as practical thereafter, if such period is not practical under Applicable Law), [***], Sanofi shall transfer and assign to RevMed all Regulatory Approvals relating to Termination Products, and, to the extent not previously provided to RevMed, transfer other Regulatory Materials including data from preclinical, non-clinical and clinical studies conducted by or on behalf of Sanofi, its Affiliates or Sublicensees on any Termination Products and all pharmacovigilance data (including all adverse event databases) on any Termination Products.', 'At the end of the sell-off period set forth in Section 12.3(c)(iii), Sanofi shall transfer to RevMed any and all inventory of SHP2 Inhibitors and Termination Products (including all research materials, final product, bulk drug substance, intermediates, work-in-process, formulation materials, reference standards, drug product clinical reserve samples, packaged retention samples, and the like) then in the possession of Sanofi, its Affiliates or Sublicensees, and continue or have continued any ongoing stability studies pertaining to any materials so transferred to RevMed for a reasonable period of time until RevMed can assume responsibility for such activities', ""If at the time of such termination, Sanofi or its Affiliates are Commercializing a particular Termination Product, then, at RevMed's request, the Parties shall negotiate in good faith a transition services agreement to cover detailing and promotion of such Termination Product (in the same manner and no more extensive than the then-current detailing and promotional efforts of Sanofi) by Sanofi or its Affiliate or contract sales force pursuant to a transition plan agreed by the Parties for a period not to exceed [***], and RevMed shall pay Sanofi a commercially reasonable amount to conduct such activities (which amount would include a commercially reasonable per-detail rate)."", ""Sanofi shall, at RevMed's request, for a period not to exceed [***] following the effective date of termination, provide reasonable technical assistance up to a total of [***] and, to the extent not already provided to RevMed, transfer copies of (including when available, in electronic format) all Sanofi Sole Program Know-How to RevMed or its designee, including without limitation: [***], in each case to the extent such materials are exclusively related to the Termination Product."", 'Within [***] after the effective date of such termination for Termination Products for which Regulatory Approval has been obtained prior to the effective date of such termination or [***] for other Termination Products (or as promptly as practical thereafter, if such period is not practical under Applicable Law), Sanofi shall transfer and assign to RevMed all Regulatory Approvals relating to such Termination Products, and, to the extent not previously provided to RevMed, transfer other Regulatory Materials including data from preclinical, non-clinical and clinical studies conducted by or on behalf of Sanofi, its Affiliates or Sublicensees on such Termination Products and all pharmacovigilance data (including all adverse event databases) on such Termination Products', 'Sanofi shall transfer and assign, and shall ensure that its Affiliates transfer and assign, to RevMed, at no cost to RevMed, all Product Marks exclusively relating to any Termination Product, provided that such Product Marks do not contain the business entity names of Sanofi or its Affiliates or variations thereof, except as may otherwise be required by Applicable Law during a transition period to avoid any interruptions in supply of Termination Product to patients. I', ""If at the time of such termination, Sanofi or its Affiliates are conducting any Clinical Trials (including Registrational Clinical Trials) of a Termination Product, then, at RevMed's election on a trial-by-trial basis, Sanofi shall cooperate, and shall ensure that its Affiliates cooperate, with RevMed to transfer the conduct of all such Clinical Trials to RevMed within [***] after the effective date of such transfer (to the extent practical in light of applicable regulatory and patient safety concerns) and RevMed shall assume any and all liability, and is liable, for such Clinical Trials conducted after the effective date of such termination (except to the extent Sanofi has an obligation of indemnification under Article XIV existing for a claim that arose prior to the effective date of such termination)."", ""In the case of a termination of this Agreement, Sanofi (with respect to the Termination Products in the Licensed Territory), shall be entitled, for a period of [***] after termination, to (i) complete Manufacture of work-in-progress, and (ii) continue conducting Commercialization activities being conducted by Sanofi hereunder as of such termination (if applicable, with respect to the terminated country(ies)), to the extent related to Termination Product in Sanofi's inventory as of such termination (or added to such inventory as a result of the completion described in clause (i)), provided that Sanofi fulfills its payment obligations under this Agreement in connection with such inventory sell-off, provided further that the payment of royalties to RevMed and the sharing of Net Profits and Net Losses under the Profit/Loss Share Agreement shall continue to apply during the sell-off period."", 'In addition to the foregoing, Sanofi shall use reasonable efforts with respect to those activities for which it is responsible hereunder to cooperate with RevMed to achieve an orderly transition of the Development, Manufacturing and Commercialization of Termination Products from Sanofi or its applicable Affiliate to RevMed.', 'Upon termination of [***] by Sanofi pursuant to Section 12.2(a)(ii)B (Termination by Sanofi for Change of Control) in the case of an Acquiror of RevMed that is a Major Biopharmaceutical Company, RevMed, [***], will (1) make available to Sanofi copies of [***], (2) provide Sanofi with copies of [***], (3) provide Sanofi with all [***], and (4) otherwise provide Sanofi all reasonable assistance in [***].', 'Each Party shall maintain complete, current and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities, for at least [***] after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law.', 'Furthermore, Sanofi shall within [***] after the effective date of such termination, transfer to RevMed all files and documents relating to the prosecution, defense or enforcement of the RevMed Licensed Patents or Joint Program Patents and provide reasonable assistance for a period not to exceed [***] following the effective date of termination, up to a total of [***], in the transfer of the prosecution, defense and enforcement responsibilities to RevMed, including by executing any documents reasonable necessary therefor.', ""At RevMed's reasonable request, for a period not to exceed [***] following the effective date of termination, Sanofi shall provide RevMed with assistance up to a total of [***] with any inquiries and correspondence with Regulatory Authorities relating to any such Termination Product."", 'With regard to Termination Products in countries for which the licenses to Sanofi are terminating, Sanofi shall provide the following transitional assistance, with costs allocated as set forth below', ""In the case of a termination of this Agreement, Sanofi (with respect to the Termination Products in the Licensed Territory), shall be entitled, for a period of [***] after termination, to (i) complete Manufacture of work-in-progress, and (ii) continue conducting Commercialization activities being conducted by Sanofi hereunder as of such termination (if applicable, with respect to the terminated country(ies)), to the extent related to such Termination Product in Sanofi's inventory as of such termination (or added to such inventory as a result of the completion described in clause (i)), provided that Sanofi fulfills its payment obligations under this Agreement in connection with such inventory sell-off, provided further that the sharing of Net Profits and Net Losses under the Profit/Loss Share Agreement shall continue to apply during the sell-off period."", 'If this Agreement is terminated in its entirety or with respect to one or more Products, other than by RevMed pursuant to Section 12.2(b) (Termination for Material Breach) or 12.2(c) (Termination for Insolvency), RevMed shall pay to Sanofi on a Product-by-Product basis royalties on sales of terminated Products (such Products, which for the purpose of clarity shall not include any Non-SHP2 Product, hereinafter referred to as ""Termination Products""), calculated based on worldwide Net Sales (as such term is applied mutatis mutandis to RevMed and including sales in the U.S.) by RevMed and its Affiliates and Sublicensees of such Termination Products as follows: [***].']"
VgrabCommunicationsInc_20200129_10-K_EX-10.33_11958828_EX-10.33_Development Agreement.pdf,Mobile Application Development Agreement,"['VAL', 'VGrab Asia Ltd.', 'Mr. Zheng Qing, Mr. Gu Xianwin and Ms. Chen Weijie']","['5th Day of March, 2019']",03-05-2019,[],Hong Kong,[],[]
AlliedEsportsEntertainmentInc_20190815_8-K_EX-10.19_11788293_EX-10.19_Content License Agreement.pdf,JOINT CONTENT LICENSE AGREEMENT,"['WPT Enterprises, Inc.', 'Zynga US', '(""Zynga Ireland,"" and together with Zynga US and their respective Affiliates, ""Zynga"").', 'ZYNGA GAME IRELAND LIMITED', 'ZYNGA INC.', 'WPT']","['February 1, 2018']",02-01-2018,"['This Agreement shall automatically extend for an additional two (2) years on the same terms herein (""Renewal Term"") provided WPT receives payments greater than twelve million U.S. dollars ($12,000,000) within the Initial Term.']",California,[],[]
DataCallTechnologies_20060918_SB-2A_EX-10.9_944510_EX-10.9_Content License Agreement.pdf,                           CONTENT LICENSING AGREEMENT,"['Data Call Technologies, Inc.', 'Licensor', 'plan_b', 'PLAN_B MEDIA AG']",['03/24/06'],04-01-2006,['The Initial Term shall automatically be           extended  for  an additional period of half a year unless either party           provides  the  other party with written notification of termination of           the  letter  Agreement  at  least 60 days prior to end of such period.'],United States,[],"['Sell-off  period:  3  months  after  termination', 'After termination  of  this  contract,  there  shall  be  a  sell-off           period  (defined  in  APPENDIX 2) following the date of termination of           this  contract.']"
GlobalTechnologiesGroupInc_20050928_10KSB_EX-10.9_4148808_EX-10.9_Content License Agreement.pdf,CONTENT LICENSE AGREEMENT,"['MobileVision Communications Ltd.', 'Distributor', 'Global Music International, Inc. d/b/a Independent Music Network', 'IMNTV']",['13/07/05'],7/13/05,"['IMNTV will extend the Agreement on the same terms and conditions for additional one-year terms, providing Distributor and IMNTV agree, predicated on satisfactory performance by both parties']",Florida,[],"['In the event that Distributor terminates this Agreement pursuant to either Section 7.2 or 7.3 above, Distributor will notify Subscribers that the Programming is no longer available.']"
IdeanomicsInc_20151124_8-K_EX-10.2_9354744_EX-10.2_Content License Agreement.pdf,FORM OF CONTENT LICENSE AGREEMENT,"['YOU ON DEMAND HOLDINGS, INC.', 'Licensor', 'Licensee', 'Beijing Sun Seven Stars Culture Development Limited']","['___________, 2015']",[]/[]/2015,[],New York,[],[]
MidwestEnergyEmissionsCorp_20080604_8-K_EX-10.2_3093976_EX-10.2_Content License Agreement.pdf,                CONTENT LICENSE AGREEMENT,"['COMPANY', 'NCM', 'YGP, LLC,', '(COMPANY and CONTENT PROVIDER are hereinafter sometimes collectively referred to as the ""Parties"").', 'New China Media LLC', 'TWK Holdings, LLC', 'TWK', '(NCM, YGP and TWK shall be individually and collectively referred to as ""CONTENT PROVIDER"")', 'YGP', 'Digicorp, Inc.', 'a/k/a New China Media Limited']","['2nd day of June, 2008']",06-02-2008,"['This Agreement shall be automatically renewed for additional extended terms each of two (2) years duration unless either party notifies the other in writing of its intention not to renew the Agreement, such notification to be provided at least ninety (90) days prior to the expiration of the then in-effect term.']",California,"[""In this regard, it is specifically understood and agreed that CONTENT PROVIDER will not during the Term of this Agreement take any action to exploit or otherwise use, reproduce, distribute, transmit and publicly display any of the Content via the internet to Universities and College students in the People's Republic of China except for the benefit of the COMPANY.""]","[""COMPANY'S obligation for the payment of the Net Advertising Revenue shall survive expiration or termination of this Agreement and will continue for as long as COMPANY continues to use the Content.""]"
